[{"text": "LIVE The latest news and updates on Trump's tariffs PREMIUM Arvinas Shares Fall Amid Breast Cancer Drug Trial Update, CCO Departure MT Newswires Fri, Jan 10, 2025, 10:37 PM 1 min read In This Article: ARVN PFE Arvinas (ARVN) shares fell 5.7% in recent Friday trading after the company outlined plans for a data PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "ARVN", "date": "2025-01-10T22:37:03", "sentiment": {"score": -0.8980827461928129, "confidence": 0.9095579981803894, "probabilities": {"positive": 0.011475251987576485, "negative": 0.9095579981803894, "neutral": 0.07896679639816284}}, "embedding": [-0.08509384840726852, -0.18755179643630981, -0.019804086536169052, 0.08409757912158966, 0.12632247805595398, -0.0009790072217583656, 0.07449345290660858, -0.047671761363744736, -0.16427990794181824, 0.09955912083387375, 0.008157584816217422, 0.14185188710689545, -0.11847668141126633, 0.05732417479157448, -0.11951786279678345, 0.008688535541296005, -0.053957320749759674, -0.13502457737922668, 0.005852394737303257, 0.16593985259532928, -0.2252570390701294, -0.13672897219657898, -0.0070134433917701244, 0.06122482940554619, 0.12537088990211487, 0.07758266478776932, -0.1175471693277359, -0.036078475415706635, -0.07183800637722015, -0.10638036578893661, -0.041806675493717194, -0.10097642987966537, 0.060619715601205826, 0.0435301810503006, -0.13046206533908844, -0.04894203320145607, -0.04331415146589279, 0.08102796971797943, 0.043858740478754044, 0.0011683152988553047, 0.14395593106746674, -0.21341587603092194, -0.19380860030651093, 0.17603346705436707, 0.02479502372443676, 0.08334732055664062, 0.05764919891953468, 0.12555605173110962, 0.10425975173711777, 0.09216760843992233, -0.13273189961910248, -0.05371030420064926, -0.009395583532750607, -0.041519660502672195, -0.03442675247788429, -0.07174807786941528, -0.15009699761867523, -0.08674101531505585, 0.05878389999270439, -0.01970241405069828, 0.06588011980056763, -0.09989520162343979, -0.09876648336648941, 0.12758754193782806, -0.021002555266022682, -0.03293386846780777, 0.08964809030294418, 0.21377769112586975, -0.0519510880112648, 0.0344255268573761, 0.17425338923931122, 0.11109708249568939, -0.12450779229402542, 0.05652143806219101, -0.10203821957111359, 0.2072070986032486, 0.31706899404525757, -0.12034409493207932, 0.22816799581050873, -0.09037026017904282, -0.03387529402971268, 0.027349010109901428, 0.04508480429649353, 0.015343300998210907, 0.04012887179851532, -0.12068217992782593, -0.04293760284781456, -0.14578184485435486, 0.027624573558568954, -0.19457922875881195, 0.25145864486694336, 0.006656746380031109, -0.005143382120877504, 0.035505808889865875, -0.1299816370010376, 0.028663529083132744, -0.0729493722319603, 0.011398485861718655, -0.2228650003671646, 0.07916082441806793, 0.03717050701379776, 0.03838122636079788, -0.09396588802337646, -0.11482805758714676, -0.1066790446639061, -0.10597128421068192, 0.01638871803879738, -0.005559000186622143, 0.0822419673204422, 0.2583877742290497, -0.08928827941417694, 0.05797591805458069, -0.0877290591597557, -0.14090445637702942, -0.1436099261045456, 0.11313556134700775, -0.050267383456230164, -0.1672433614730835, -0.03421245142817497, -0.03398283198475838, -0.13998785614967346, 0.2190219610929489, -0.08417653292417526, 0.057749200612306595, -0.0239768847823143, 0.021756794303655624, -0.06860517710447311, 1.3383491014267335e-32, -0.12596412003040314, 0.026529977098107338, -0.011662463657557964, -0.07808590680360794, 0.07704777270555496, 0.05326119810342789, -0.009736530482769012, -0.21007724106311798, -0.14937745034694672, -0.09060968458652496, -0.20957888662815094, 0.17985191941261292, -0.12892097234725952, 0.06760762631893158, -0.056216977536678314, -0.15803687274456024, 0.002681843936443329, 0.10137666761875153, 0.09233370423316956, -0.029756082221865654, 0.005017571151256561, -0.01947185769677162, -0.056077588349580765, 0.08271099627017975, -0.002659472171217203, 0.11158981174230576, 0.07177241146564484, -0.05529326573014259, 0.016925964504480362, 0.09102462232112885, -0.10382173955440521, 0.1335429847240448, 0.03146833926439285, -0.07658011466264725, -0.08522161841392517, 0.06593935191631317, -0.047980502247810364, 0.021558579057455063, -0.027109406888484955, -0.0712367594242096, -0.02408282645046711, 0.030535604804754257, -0.006962916813790798, 0.10679086297750473, -0.06972482800483704, -0.1491670459508896, -0.06142843887209892, -0.06325221806764603, 0.09020832926034927, -0.11612417548894882, -0.06914158165454865, -0.01605875790119171, -0.11683865636587143, -0.09427300095558167, -0.008137829601764679, 0.010406898334622383, -0.1711629033088684, -0.11149805784225464, 0.18273089826107025, -0.10058939456939697, 0.22847424447536469, 0.056033991277217865, 0.08093171566724777, 0.05443441495299339, -0.21654058992862701, 0.12654629349708557, -0.08142730593681335, -0.04178783670067787, -0.10663746297359467, 0.12521982192993164, 0.14668717980384827, -0.03446967527270317, 0.07360909879207611, -0.1137317642569542, -0.032276250422000885, 0.13910987973213196, -0.09496720880270004, -0.017967522144317627, 0.17489945888519287, 0.06297745555639267, -0.05913567170500755, -0.12146176397800446, 0.2813293933868408, 0.12611491978168488, 0.074434794485569, 0.04782017692923546, 0.0941302478313446, -0.00523761473596096, -0.01985449530184269, 0.012852348387241364, 0.06800486147403717, 0.036360614001750946, 0.05964815616607666, -0.09622423350811005, 0.06388677656650543, -1.417563020866358e-32, -0.11957128345966339, 0.06401221454143524, -0.010305304080247879, -0.09406248480081558, -0.15385854244232178, 0.020566416904330254, 0.051525771617889404, 0.13799014687538147, 0.09025353938341141, 0.12296468019485474, -0.0029392605647444725, -0.03856687992811203, -0.15269087255001068, 0.08800681680440903, -0.01842963881790638, -0.05681084841489792, 0.2313840240240097, -0.03213070333003998, 0.024781359359622, -0.07530021667480469, 0.012535076588392258, 0.11438721418380737, -0.17111214995384216, 0.3028477132320404, 0.011388292536139488, -0.08241088688373566, 0.19272883236408234, 0.02744274213910103, 0.05830756574869156, -0.17621615529060364, -0.113971047103405, -0.06447287648916245, -0.18470150232315063, 0.14605724811553955, 0.033326976001262665, 0.03278914839029312, 0.15616759657859802, 0.0862550213932991, -0.09084656089544296, -0.11814118176698685, 0.22712285816669464, -0.036426834762096405, -0.08798106014728546, 0.06669577211141586, 0.04943297058343887, 0.07241596281528473, 0.025010408833622932, 0.05638984590768814, 0.10247822850942612, -0.14200201630592346, 0.04338447377085686, 0.0433134101331234, -4.147551953792572e-05, 0.2070898711681366, -0.10999544709920883, 0.03206488862633705, 0.031247641891241074, 0.03670690208673477, -0.0895933136343956, 0.020877551287412643, -0.04548905789852142, 0.050239283591508865, -0.1797792911529541, -0.1383105367422104, 0.01782958209514618, 0.11159811168909073, -0.036280542612075806, -0.06118226423859596, 0.06603185087442398, -0.10916466265916824, 0.09175875037908554, -0.08125317841768265, -0.042989470064640045, -0.20012524724006653, 0.04191930219531059, 0.1441957652568817, 0.06986221671104431, -0.022955887019634247, 0.04123756289482117, 0.0208286065608263, 0.17846380174160004, -0.1107834130525589, -0.026087263599038124, 0.042891062796115875, -0.08807870745658875, 0.042692881077528, 0.1017281711101532, -0.013441345654428005, -0.08254125714302063, 0.1364494264125824, -0.22912916541099548, -0.14243444800376892, -0.11778901517391205, 0.03669886291027069, -0.019345097243785858, -1.0012369244805086e-07, 0.13377521932125092, -0.05219993367791176, 0.10552443563938141, 0.050561875104904175, -0.005484920926392078, 0.04667732119560242, -0.07963316887617111, -0.040560878813266754, 0.01326718833297491, 0.1802496314048767, 0.020735880360007286, 0.03147326409816742, -0.018973201513290405, -0.009327798150479794, -0.0377340242266655, -0.010044386610388756, 0.12055302411317825, 0.19934119284152985, 0.008511348627507687, -0.06747779250144958, -0.03073975443840027, 0.22889059782028198, 0.0009582862257957458, -0.0724564716219902, 0.03370106592774391, 0.04942990094423294, -0.056155215948820114, -0.027798444032669067, 0.035128794610500336, -0.07074076682329178, -0.030164577066898346, -0.02184847556054592, -0.07191773504018784, -0.009638436138629913, 0.01359929982572794, 0.05157651752233505, 0.050695598125457764, -0.028951913118362427, 0.0955086201429367, 0.011183868162333965, -0.11935646086931229, -0.057974595576524734, 0.14128407835960388, -0.013789125718176365, -0.08875739574432373, 0.025675158947706223, -0.10582900792360306, -0.13353314995765686, 0.24627386033535004, -0.03744322061538696, 0.05820596590638161, -0.05990578606724739, 0.16144302487373352, -0.09425321221351624, -0.0309776421636343, 0.00018137600272893906, -0.04929376021027565, -0.12030286341905594, -0.06309071183204651, 0.010954972356557846, 0.1733970195055008, -0.254920095205307, -0.06551092863082886, 0.23557394742965698], "changes": {"1wk": -3.0612329564015153}}, {"text": "LIVE The latest news and updates on Trump's tariffs Arvinas Updates Guidance for First- and Second-Line Phase 3 Combination Trials with Vepdegestrant, Highlights Upcoming Milestones, and Provides Corporate Update Arvinas Inc. Fri, Jan 10, 2025, 3:00 PM 7 min read In This Article: ARVN Arvinas Inc. \u2013 Vepdegestrant to be combined with Pfizer\u2019s novel investigational CDK4 inhibitor atirmociclib in a first-line Phase 3 trial planned to initiate in 2025; a second-line Phase 3 combination trial will combine vepdegestrant with a CDK4/6 inhibitor, also planned to initiate in 2025 \u2013 \u2013 Topline data from the monotherapy Phase 3 VERITAC-2 trial of vepdegestrant anticipated in 1Q25 \u2013 \u2013 The Company recently initiated a Phase 1 trial with PROTAC LRRK2 degrader ARV-102 in patients with Parkinson\u2019s disease \u2013 \u2013 Data disclosures anticipated from multiple clinical and pre-clinical programs, including ARV-102 and ARV-393, and planned IND submission for a PROTAC KRAS G12D degrader in 2025 \u2013 NEW HAVEN, Conn., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced updated guidance for the planned first- and second-line combination clinical trials for vepdegestrant in patients with locally advanced or metastatic estrogen receptor positive (ER+)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer, highlighted key upcoming milestones and provided a corporate update. \u201cWe are on the cusp of a major transformation in 2025, with the potential to provide significant benefit to patients and meaningful value to our stockholders,\u201d said John Houston, Ph.D., Chairperson, Chief Executive Officer and President at Arvinas. \u201cWe are on track to report topline results from our first Phase 3 trial in the first quarter and to initiate two additional Phase 3 trials by the end of the year. In the first half of 2025, we plan to present the first-in-human data from ARV-102, our PROTAC LRRK2 degrader, which we believe will highlight the potential value that our PROTAC degraders may offer for patients with neurodegenerative diseases. And finally, we plan to share initial data from our Phase 1 trial with ARV-393, our PROTAC BCL6 degrader, which will provide an early look the tolerability and efficacy in patients with B-cell lymphomas.\u201d Select milestones anticipated in 2025 Vepdegestrant: Oral PROTAC ER degrader As part of Arvinas\u2019 global collaboration with Pfizer, in 2025 the companies plan to: Announce topline data for the VERITAC-2 Phase 3 monotherapy clinical trial in patients with second-line-plus ER+/HER2- metastatic breast cancer (mBC) (1Q25). Initiate two new Phase 3 combination trials in patients with ER+/HER2- mBC (pending emerging data and regulatory feedback): First-line Phase 3 combination trial with Pfizer\u2019s novel investigational CDK4 inhibitor, atirmociclib. Second-line Phase 3 combination trial with a CDK4/6 inhibitor. Story Continues With the prioritization of the vepdegestrant plus atirmociclib combination for the first-line setting, the VERITAC-3 trial evaluating vepdegestrant plus palbociclib in the first-line will not proceed beyond the study lead-in. ARV-102: Oral PROTAC LRRK2 degrader Present single-ascending dose data from the ongoing Phase 1 clinical trial in healthy volunteers in an oral session at the Alzheimer\u2019s Disease/Parkinson\u2019s Disease (AD/PD) conference in Vienna, Austria (April 1-4, 2025). Complete enrollment and present initial data from the ongoing Phase 1 clinical trial in patients with Parkinson\u2019s disease. ARV-393: Oral PROTAC BCL6 degrader Present initial data from the ongoing Phase 1 clinical trial in patients with B-cell lymphomas (NCT06393738). Novel PROTAC KRAS G12D degrader File an Investigational New Drug (IND) application. Corporate update Alex Santini, Arvinas\u2019 Senior Vice President, Global and U.S. Market Access, has been appointed interim Chief Commercial Officer, effective January 17, 2025. Mr. Santini joined Arvinas in 2023 with more than 30 years of experience managing and leading commercial organizations. Previously, he was Executive Vice President, Chief Commercial Officer, at Lexicon Pharmaceuticals. Prior to Lexicon, Mr. Santini was Executive Vice President, U.S. Market Access at Bayer, where he served on the U.S. Executive Committee. Mr. Santini\u2019s prior experience also includes serving as Senior Vice President, Market Access at Nektar Therapeutics, and he began his career at Berlex Laboratories, where he served in roles of increasing responsibility in the commercial organization. John Northcott, Chief Commercial Officer, is leaving the Company for personal reasons, effective January 17, 2025. \u201cOur commercial organization couldn\u2019t be in a better position, and I look forward to working closely with Alex,\u201d continued Dr. Houston. \u201cHe has been a highly valued member of the Arvinas team for multiple years, and his well-established ability to build and lead an outstanding commercial team will be invaluable as we prepare for our potential first launch alongside our partners at Pfizer. We thank John for his contributions to the business, particularly his efforts to begin building a strong commercial organization for launch.\u201d About Vepdegestrant Vepdegestrant is an investigational, orally bioavailable PROTAC protein degrader designed to specifically target and degrade the estrogen receptor (ER) for the treatment of patients with ER positive (ER+)/human epidermal growth factor receptor 2 (HER2) negative (ER+/HER2-) breast cancer. Vepdegestrant is being developed as a potential monotherapy and as part of combination therapy across multiple treatment settings for ER+/HER2- metastatic breast cancer. In July 2021, Arvinas announced a global collaboration with Pfizer for the co-development and co-commercialization of vepdegestrant; Arvinas and Pfizer will share worldwide development costs, commercialization expenses, and profits. The U.S. Food and Drug Administration (FDA) has granted vepdegestrant Fast Track designation as a monotherapy in the treatment of adults with ER+/HER2- locally advanced or metastatic breast cancer previously treated with endocrine-based therapy. About\u00a0Arvinas Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC \u00ae (PROteolysis Targeting Chimera) protein degrader platform, the Company is pioneering the development of protein degradation therapies designed to harness the body\u2019s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; and ARV-102, targeting LRRK2 for neurodegenerative disorders. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit www.arvinas.com and connect on LinkedIn and X . Forward-Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding the plans and expected timing of initiation of two Phase 3 vepdegestrant combination clinical trials, in the first- and second-line settings, pending emerging data and regulatory feedback; the expected timing to report topline data from the VERITAC-2 Phase 3 monotherapy clinical trial of vepdegestrant; the potential to provide significant benefit to patients and meaningful value to stockholders in 2025; the plans and timing of presentation of first-in-human data from ARV-102 and the company\u2019s belief that such data will highlight the potential value that its PROTAC degraders may offer patients with neurodegenerative diseases; the plans and timing of sharing initial data from the company\u2019s Phase 1 clinical trial of ARV-393; and the plans and expected timing of filing an investigational new drug application for a PROTAC KRAS G12D degrader. All statements, other than statements of historical fact, contained in this press release, including statements regarding Arvinas\u2019 strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words \u201canticipate,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cplan,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201ctarget,\u201d \u201cgoal,\u201d \u201cpotential,\u201d \u201cwill,\u201d \u201cwould,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201ccontinue,\u201d and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Arvinas may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on such forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements Arvinas makes as a result of various risks and uncertainties, including but not limited to: Arvinas\u2019 and Pfizer\u2019s performance of the respective obligations with respect to Arvinas\u2019 collaboration with Pfizer; whether Arvinas and Pfizer will be able to successfully conduct and complete clinical development for vepdegestrant; whether Arvinas will be able to successfully conduct and complete development for its other product candidates, including whether Arvinas initiates and completes clinical trials for its product candidates and receives results from its clinical trials on its expected timelines or at all; Arvinas\u2019 ability to protect its intellectual property portfolio; whether Arvinas\u2019 cash and cash equivalent resources will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements, and other important factors discussed in the \u201cRisk Factors\u201d section of Arvinas\u2019 Annual Report on Form 10-K for the year ended December 31, 2023 and subsequent other reports, including its quarterly reports, on file with the U.S. Securities and Exchange Commission. The forward-looking statements contained in this press release reflect Arvinas\u2019 current views with respect to future events, and Arvinas assumes no obligation to update any forward-looking statements, except as required by applicable law. These forward-looking statements should not be relied upon as representing Arvinas\u2019 views as of any date subsequent to the date of this release. Contacts Investors: Jeff Boyle +1 (347) 247-5089 Jeff.Boyle@arvinas.com Media: Kirsten Owens +1 (203) 584-0307 Kirsten.Owens@arvinas.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "ARVN", "date": "2025-01-10T15:00:00", "sentiment": {"score": 0.6931939199566841, "confidence": 0.7025609612464905, "probabilities": {"positive": 0.7025609612464905, "negative": 0.009367041289806366, "neutral": 0.28807201981544495}}, "embedding": [-0.16170571744441986, -0.14797306060791016, -0.06323238462209702, -0.07921560853719711, 0.16647182404994965, -0.09231813251972198, -0.20078560709953308, 0.213732048869133, 0.050769783556461334, 0.08123579621315002, -0.02011767588555813, 0.14737477898597717, -0.018270332366228104, -0.014130610041320324, -0.012346351519227028, 0.1437254697084427, -0.0641493946313858, 0.03794748708605766, 0.04200197011232376, 0.08334284275770187, -0.007512114010751247, -0.06776218861341476, 0.04311515390872955, 0.10918915271759033, -0.09491604566574097, 0.0005051959306001663, -0.08225125819444656, 0.008278751745820045, -0.14717502892017365, -0.08036243915557861, 0.12320467829704285, 0.102275550365448, -0.06100773438811302, 0.018261699005961418, 0.0014439122751355171, 0.045442745089530945, -0.17792688310146332, 0.09327719360589981, -0.08922234922647476, -0.14664044976234436, 0.05466119199991226, -0.11938649415969849, -0.12158026546239853, -0.016769174486398697, 0.09375763684511185, -0.10234807431697845, -0.0688069611787796, 0.02888868749141693, -0.031763073056936264, 0.14199720323085785, 0.03954945132136345, -0.07245160639286041, -0.035297542810440063, 0.12438850849866867, -0.10151064395904541, -0.03251280635595322, -0.10256470739841461, 0.014558701775968075, -0.012800929136574268, 0.1216985285282135, 0.030859440565109253, -0.05058981850743294, -0.079538494348526, -0.05820174887776375, 0.03753671422600746, 0.0290406234562397, 0.028588496148586273, -0.012265201658010483, 0.01342000626027584, 0.07786571234464645, 0.017352990806102753, 0.01452242024242878, 0.060366563498973846, 0.10775907337665558, -0.038093894720077515, 0.06426642835140228, 0.08131936192512512, 0.1284083127975464, 0.1376309096813202, -0.21541015803813934, 0.01842331886291504, 0.06525291502475739, 0.07253581285476685, -0.0307704396545887, -0.08863961696624756, -0.022939033806324005, -0.13163596391677856, 0.06005968153476715, 0.050895243883132935, -0.03195295110344887, 0.23546157777309418, -0.002368604764342308, -0.024437639862298965, 0.05912264436483383, -0.000644155777990818, 0.04309583082795143, -0.05382256209850311, -0.04236166924238205, 0.04557822272181511, 0.0022008195519447327, 0.0014037610962986946, 0.013389292173087597, -0.11348100006580353, -0.16733059287071228, -0.06522417813539505, -0.12351609766483307, 0.1328740417957306, -0.13090337812900543, 0.049877334386110306, 0.028853576630353928, 0.014596957713365555, -0.04520507529377937, 0.09188444912433624, 0.024010129272937775, 0.024532221257686615, 0.20680320262908936, -0.02853543683886528, 0.042341720312833786, 0.19130992889404297, -0.1113080233335495, -0.00483740633353591, 0.03559531271457672, 0.04158607870340347, -0.07344424724578857, 0.11166456341743469, 0.03178536519408226, -0.07587285339832306, 1.1408409242968403e-32, -0.013991577550768852, -0.042521122843027115, 0.054193515330553055, 0.09545042365789413, 0.012028023600578308, -0.008645689114928246, 0.03881305083632469, -0.06962831318378448, -0.0828055664896965, -0.060270488262176514, -0.12486028671264648, -0.07927528023719788, -0.021963216364383698, 0.096366748213768, -0.07669363170862198, -0.0757075846195221, -0.05831528082489967, 0.11847291141748428, -0.052978307008743286, 0.02470516599714756, 0.12151449918746948, -0.020167771726846695, -0.019510112702846527, -0.033192507922649384, 0.018189476802945137, 0.15331634879112244, -0.029462840408086777, 0.08598165214061737, 0.05250097066164017, 0.04583100229501724, -0.17434027791023254, 0.08479049801826477, 0.00488673709332943, 0.020742952823638916, -0.10674326121807098, -0.07205864787101746, -0.0688081681728363, -0.08390293270349503, 0.078079953789711, 0.08945682644844055, 0.09042411297559738, 0.08859661966562271, -0.04758600890636444, -0.10172593593597412, 0.006748504471033812, -0.14685437083244324, 0.053214795887470245, 0.10455504059791565, 0.007860756479203701, -0.10331611335277557, 0.05730518698692322, -0.05717434734106064, -0.02926533669233322, -0.07877236604690552, -0.06170424446463585, -0.024005044251680374, -0.13254810869693756, -0.10352469980716705, 0.1502610743045807, 0.03573000058531761, 0.09941969811916351, 0.025126587599515915, 0.0058461325243115425, 0.03479492664337158, -0.031678490340709686, -0.007499211467802525, -0.020972568541765213, -0.08038146048784256, -0.05047524720430374, 0.08211392164230347, -0.04592413455247879, -0.04648172855377197, 0.21382807195186615, 0.020606275647878647, 0.17680588364601135, -0.04945317655801773, 0.06230109557509422, 0.19626691937446594, 0.02893010899424553, 0.09086096286773682, -0.18602189421653748, 0.03738432377576828, -0.15582148730754852, 0.16804790496826172, 0.06663653254508972, -0.10248993337154388, 0.017774833366274834, -0.08213266730308533, -0.17289921641349792, 0.015451433137059212, 0.07569613307714462, -0.014906803146004677, -0.017561210319399834, 0.17168959975242615, 0.0918559804558754, -1.0826513825372447e-32, -0.07971499860286713, 0.033307574689388275, 0.027092397212982178, -0.0465228334069252, -0.006730562075972557, 0.15089425444602966, 0.13519886136054993, -0.08755602687597275, 0.21363936364650726, -0.11164049804210663, 0.1157570481300354, 0.0419076643884182, -0.01851625367999077, -0.021350625902414322, -0.01388535276055336, 0.018553046509623528, -0.10753519833087921, -0.018880993127822876, -0.06774334609508514, 0.055357325822114944, 0.09443491697311401, 0.12602248787879944, -0.07554720342159271, 0.06092090904712677, 0.05402878671884537, 0.03902564197778702, 0.23919187486171722, 0.07307422161102295, 0.03529749810695648, -0.08297054469585419, -0.06393247842788696, -0.024931160733103752, -0.22471827268600464, 0.05615599453449249, -0.013250558637082577, -0.04874038323760033, 0.0685415267944336, -0.2296949326992035, -0.09184698760509491, -0.1301397979259491, 0.1632392704486847, 0.1607264131307602, -0.1514049470424652, -0.05966624617576599, 0.012062938883900642, -0.036856792867183685, 0.07701456546783447, 0.038402166217565536, 0.1972026526927948, -0.11659405380487442, 0.00946864765137434, -0.03322207182645798, -0.0491291768848896, 0.013712538406252861, -0.03340288996696472, -0.10867352783679962, 0.005769897252321243, -0.01662987470626831, -0.0657380074262619, 0.08150456845760345, -0.15403056144714355, 0.07827575504779816, -0.019183360040187836, 0.023241396993398666, 0.08261392265558243, 0.16058534383773804, 0.1604616940021515, 0.02674504742026329, 0.10506469011306763, -0.01356362085789442, -0.04114241153001785, -0.03742138296365738, -0.038421835750341415, -0.012916513718664646, 0.04075809195637703, 0.09973139315843582, 0.07637230306863785, -0.16899366676807404, -0.07641077786684036, -0.14890709519386292, -0.02810676395893097, -0.12907204031944275, -0.04807861149311066, 0.009417512454092503, 0.06249693036079407, 0.07082818448543549, -0.055170368403196335, 0.16135583817958832, 0.05481511354446411, 0.08111695945262909, -0.08199073374271393, -0.11218184232711792, -0.11288965493440628, 0.18729016184806824, 0.0017202403396368027, -9.994612071295705e-08, 0.06423892825841904, -0.006065757945179939, 0.03095845878124237, -0.09034210443496704, 0.0038622175343334675, -0.03189367800951004, -0.0881572812795639, 0.050432249903678894, -0.09002278000116348, 0.040186796337366104, 0.11669585108757019, 0.14316824078559875, -0.003242899663746357, -0.16042962670326233, -0.03961030766367912, 0.07481294125318527, 0.06860221922397614, 0.10348765552043915, -0.07851341366767883, -0.08391690999269485, -0.06808336079120636, -0.032407574355602264, -0.013189099729061127, -0.1255694031715393, 0.0947219580411911, -0.06111399084329605, -0.006730689667165279, 0.13737168908119202, 0.04976237565279007, -0.18289814889431, 0.07822921127080917, -0.053876377642154694, 0.05941899120807648, 0.06301633268594742, 0.08874952048063278, -0.049668677151203156, 0.015218459069728851, 0.06561203300952911, 0.09872112423181534, 0.10768453031778336, -0.015620618127286434, 0.061522193253040314, -0.06167462095618248, -0.013823555782437325, -0.14081396162509918, -0.12252666801214218, -0.1206965297460556, -0.10382305830717087, -0.016201453283429146, -0.07272522151470184, -0.05012178793549538, 0.0059367939829826355, 0.034925226122140884, -0.1040286123752594, 0.026703523471951485, 0.13114631175994873, -0.17113780975341797, -0.09644986689090729, -0.023879611864686012, -0.12236933410167694, 0.16784197092056274, -0.11549408733844757, -0.05240152031183243, 0.08462794870138168], "changes": {"1wk": -5.585396716717664}}, {"text": "LIVE The latest news and updates on Trump's tariffs 2 Growth Stocks That Could Rocket Higher in the First Quarter of 2025 Cory Renauer, The Motley Fool Tue, Jan 21, 2025, 12:29 PM 4 min read In This Article: RXRX ARVN Investors looking for stocks that could make dramatic moves in a short, defined time frame will want to turn their attention toward two innovative drugmakers. A couple of stocks in the volatile biopharmaceutical industry are poised to soar by the end of March. Results from clinical trials that wrap up soon could soon push shares of Recursion Pharmaceuticals (NASDAQ: RXRX) , and Arvinas (NASDAQ: ARVN) through the roof. Both companies are expected to report their highly anticipated data any day now. Before you get excited and fill your portfolio with shares of these drugmakers, it's important to realize positive outcomes regarding their upcoming catalysts are a long way from guaranteed. Read on to see why these stocks could be worth further inspection. 1. Recursion Pharmaceuticals In a nutshell, Recursion Pharmaceuticals is using artificial intelligence (AI) software to speed up the pace of drug development. The stock soared in 2023 when Nvidia disclosed a small equity stake. Unfortunately, Recursion stock has fallen around 59% from its previous peak because investors are still waiting for clinical validation of its AI-powered drug discovery platform. Recursion Pharmaceuticals was founded in 2013 and received its first green light to begin a clinical trial with REC-994, an experimental drug it discovered with help from its AI-driven discovery platform in 2018. Unfortunately, REC-994 for cerebral cavernous malformation failed to improve outcomes for patients with the rare neurovascular condition in a phase 1 study that read out last September. Recursion disappointed investors further with its second clinical trial flop last December. The Elucidate study enrolled 19 ovarian cancer patients and treated them with REC-617, a CDK7 inhibitor similar to Verzenio from Eli Lilly . One out of 18 evaluable patients responded to the candidate Recursion described as potentially best in class. Recursion's stock has been justifiably beaten down in response to dismal clinical data so far. Now that its market cap has dwindled down to about $1.9 billion, clinical validation of its platform could send the stock soaring. A phase 2 trial with REC-2282 and neurofibromatosis patients was supposed to read out results in late 2024 and could produce data any day now. A successful readout for REC-2282 could send Recursion stock soaring. After two consecutive trial failures, though, it isn't worth the risk. It's best to wait until after we see a candidate from its AI-driven platform produce better outcomes for patients. 2. Arvinas Arvinas is another clinical-stage drug developer with a somewhat unproven drug discovery platform. Instead of AI, it's focused on getting cells to degrade troublemaking proteins once considered unassailable. Story Continues Arvinas' lead candidate, vepdegestrant, is an orally available estrogen receptor degrader that the company is co-developing in partnership with Pfizer . The phase 3 Veritac-2 study finished enrolling second-line breast cancer patients in late 2024, and the study could produce top-line results any day now. Patients in the Veritac-2 study were randomized to receive a standard estrogen blocker called fulvestrant, or Arvinas' vepdegestrant. If the experimental estrogen degrader delays tumor growth longer than the standard of care, this stock will rocket higher. In a few years, vepdegestrant sales could soar past $1 billion annually if it outperforms the standard of care in Veritac-2 and subsequent trials. Unlike Recursion, Arvinas already validated its discovery platform with phase 2 results that showed a 38% response rate among second-line breast cancer patients treated with vepdegestrant monotherapy. Arvinas stock has fallen by more than half from a peak it set last spring. At its beaten-down price, the drugmaker sports an extremely modest $119 million enterprise value . With Pfizer doing a lot of the heavy lifting, Arvinas burned through just $154 million during the first nine months of 2024. A modest cash burn rate left the company with an extremely healthy $1.1 billion cash position. There are no guarantees that vepdegestrant will outperform the standard of care, but its chances of success appear better than average. Adding some shares of this stock to a diverse portfolio now could be a smart move for investors with a strong risk tolerance. Should you invest $1,000 in Recursion Pharmaceuticals right now? Before you buy stock in Recursion Pharmaceuticals, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now\u2026 and Recursion Pharmaceuticals wasn\u2019t one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you\u2019d have $843,960 !* Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*. See the 10 stocks \u00bb *Stock Advisor returns as of January 13, 2025 Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Nvidia and Pfizer. The Motley Fool has a disclosure policy . 2 Growth Stocks That Could Rocket Higher in the First Quarter of 2025 was originally published by The Motley Fool View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "ARVN", "date": "2025-01-21T12:29:00", "sentiment": {"score": -0.764042466878891, "confidence": 0.842559278011322, "probabilities": {"positive": 0.07851681113243103, "negative": 0.842559278011322, "neutral": 0.07892388105392456}}, "embedding": [-0.10111959278583527, -0.2533418536186218, -0.05027487128973007, -0.09390479326248169, -0.015068589709699154, -0.08889655768871307, -0.04370035231113434, 0.15403561294078827, 0.09902331233024597, 0.07573587447404861, -0.1263125091791153, 0.1675812155008316, 0.0005559828132390976, 0.040140554308891296, -0.15625399351119995, 0.0486375167965889, 0.019987909123301506, -0.009585399180650711, -0.04617319256067276, 0.05985264107584953, -0.12050707638263702, -0.07695308327674866, 0.047561317682266235, -0.002080155536532402, 0.030675416812300682, 0.08329948782920837, -0.054947443306446075, -0.09404421597719193, -0.13295117020606995, -0.10232768207788467, 0.19384539127349854, 0.16118668019771576, 0.048572368919849396, -0.08553944528102875, -0.08088963478803635, 0.07748889178037643, -0.07220961153507233, 0.051351457834243774, 0.038149185478687286, 0.023335464298725128, -0.05258568376302719, -0.12295985966920853, -0.08684632927179337, 0.1137315034866333, 0.14491327106952667, -0.18231680989265442, -0.0656534880399704, 0.012712251394987106, 0.08401109278202057, 0.07687024027109146, -0.19440922141075134, -0.1206464171409607, -0.01789051853120327, 0.020104514434933662, -0.07749511301517487, 0.043845515698194504, -0.1372143030166626, -0.0008487673476338387, 0.03944890946149826, 0.0047753192484378815, 0.14550426602363586, -0.09882965683937073, 0.05187399312853813, -0.005740887485444546, 0.045631296932697296, 0.08259089291095734, 0.045549385249614716, -0.05525008961558342, 0.040999915450811386, 0.01971195638179779, 0.25142210721969604, 0.013391658663749695, -5.3583644330501556e-05, 0.06975377351045609, -0.07235050201416016, 0.10080444812774658, 0.1305253803730011, 0.1314997375011444, 0.2413150668144226, -0.1801772564649582, 0.09816108644008636, 0.017551496624946594, 0.053192369639873505, -0.013657128438353539, -0.02784469909965992, -0.01828390546143055, 0.09803822636604309, 0.13010387122631073, 0.1227518618106842, -0.06264117360115051, 0.1502191722393036, -0.011755906045436859, 0.026670970022678375, -0.025071918964385986, -0.06364233046770096, 0.00920126959681511, -0.1028890311717987, -0.0272175632417202, -0.01627260074019432, 0.015505392104387283, 0.019498420879244804, 0.04126714915037155, -0.05929523706436157, -0.13222746551036835, -0.12427598237991333, -0.07254736125469208, 0.053844794631004333, -0.04956142604351044, 0.05555570870637894, 0.001413273625075817, -0.15114369988441467, 0.11368658393621445, 0.030440928414463997, 0.015689652413129807, -0.10590879619121552, 0.19829994440078735, -0.07392332702875137, -0.018024254590272903, 0.10125306248664856, 0.04304471239447594, -0.02192367985844612, 0.02492741122841835, -0.04862545430660248, -0.11827273666858673, 0.16704100370407104, 0.032600075006484985, -0.19185921549797058, 1.5830574909723693e-32, -0.14572250843048096, 0.06547246873378754, 0.02452397719025612, 0.026451116427779198, -0.0193601306527853, 0.021074190735816956, 0.07353605329990387, 0.018000666052103043, -0.14505913853645325, -0.09079260379076004, -0.16267827153205872, 0.07476858794689178, -0.06718970090150833, 0.05536509305238724, -0.0037316642701625824, -0.20061710476875305, 0.0012918394058942795, 0.033414170145988464, -0.06600840389728546, -0.12619951367378235, 0.015691474080085754, -0.06641868501901627, -0.058409810066223145, 0.011347362771630287, -0.03931252658367157, 0.01593524031341076, -0.06176523491740227, 0.0691058561205864, 0.1360573172569275, 0.02840559370815754, -0.06326015293598175, 0.10855241864919662, -0.03647317737340927, -0.009112253785133362, -0.08674308657646179, -0.05770455300807953, -0.11719617247581482, -0.1005319356918335, 0.09259361028671265, 0.1558952033519745, -0.042045436799526215, 0.18490786850452423, -0.10246060788631439, -0.07874032855033875, 0.003394289407879114, -0.052403904497623444, -0.1140228658914566, -0.014310916885733604, -0.048194460570812225, 0.008978260681033134, -0.059223517775535583, 0.09451444447040558, 0.021785980090498924, -0.07006227225065231, 0.04787251353263855, 0.021271131932735443, -0.22889778017997742, -0.059196837246418, 0.08632870018482208, 0.055555783212184906, 0.07668173313140869, 0.13606223464012146, -0.05933947116136551, 0.06717817485332489, -0.1937301605939865, 0.16076453030109406, 0.07597652822732925, 0.002846307121217251, -0.10183461010456085, 0.24573801457881927, 0.08333505690097809, -0.017003091052174568, 0.047383055090904236, -0.1309027373790741, 0.11656685173511505, -0.11646564304828644, 0.007417920045554638, 0.00899934209883213, 0.03408860042691231, -0.02148227021098137, -0.00816062930971384, -0.033215466886758804, -0.017587561160326004, 0.17467540502548218, -0.014356555417180061, -0.09898051619529724, -0.023492787033319473, 0.06801237165927887, -0.09078705310821533, -0.016993436962366104, 0.007629348896443844, -0.12117776274681091, -0.022775255143642426, 0.056591570377349854, 0.0533304288983345, -1.306480567955178e-32, -0.03508774936199188, -0.06173386797308922, 0.0014653911348432302, -0.05023746192455292, 0.021466689184308052, 0.03473624587059021, 0.0672585591673851, -0.13555800914764404, 0.10358019173145294, -0.0717945396900177, 0.01229148730635643, 0.04432566836476326, 0.010123399086296558, 0.03003799356520176, -0.04970971867442131, -0.038857731968164444, 0.05344267189502716, -0.13793502748012543, -0.010147299617528915, -0.12129218876361847, 0.016141291707754135, 0.14177171885967255, -0.17388790845870972, 0.08601386845111847, -0.017383694648742676, 0.1110592782497406, 0.06956104189157486, 0.10516373813152313, 0.053987737745046616, -0.03733617812395096, -0.14112864434719086, -0.012822550721466541, -0.2111114114522934, 0.0759882777929306, 0.024095455184578896, 0.07826244831085205, 0.055884867906570435, -0.14779189229011536, -0.04064967855811119, -0.07579896599054337, 0.14578700065612793, 0.07173663377761841, -0.057041920721530914, 0.009622910991311073, 0.0453348383307457, -0.05310066044330597, 0.039338450878858566, 0.10609308630228043, 0.19058118760585785, -0.07861547917127609, 0.0012886381009593606, 0.0473356768488884, 0.006423959508538246, -0.032918184995651245, -0.06559336185455322, 0.034353166818618774, -0.032662533223629, -0.05282968655228615, -0.038411542773246765, 0.0747464969754219, -0.08949445188045502, 0.001623021438717842, 0.020490432158112526, -0.01585073210299015, -0.03114643692970276, 0.06338094174861908, 0.058283042162656784, 0.09373350441455841, 0.06796003133058548, -0.1328396499156952, 0.06041283160448074, -0.030437465757131577, -0.02463352680206299, 0.007792516611516476, -0.05946575850248337, 0.11254788190126419, -0.012912658974528313, -0.13843712210655212, -0.0802786648273468, -0.09567083418369293, 0.10659700632095337, -0.07606305181980133, 0.05520759895443916, 0.0283687524497509, 0.03991282358765602, 0.13080713152885437, 0.02819851040840149, -0.05494512617588043, -0.04183914512395859, 0.01824488490819931, -0.05262129381299019, -0.15665407478809357, -0.05885431170463562, 0.1694308966398239, 0.05714428797364235, -1.0064870537007664e-07, 0.10319311171770096, -0.07852200418710709, 0.10325750708580017, -0.045063745230436325, 0.18746837973594666, -0.05557716637849808, -0.03782638907432556, 0.09839384257793427, 0.020961932837963104, 0.09550400078296661, 0.09518713504076004, 0.07462852448225021, -0.10565111041069031, 0.0803922563791275, 0.011804886162281036, 0.12413439154624939, -0.03024871088564396, 0.016728920862078667, -0.07812907546758652, -0.0706639289855957, -0.019572995603084564, 0.054160915315151215, 0.0390741303563118, -0.024318024516105652, 0.07370179891586304, -0.05476442724466324, 0.04900950938463211, -0.030983440577983856, -0.032636210322380066, 0.03155826777219772, -0.009427391923964024, -0.013499202206730843, 0.1769835352897644, 0.06664864718914032, 0.0698656290769577, -0.11744119226932526, 0.09692820906639099, 0.11773128807544708, -0.015250086784362793, -0.07892034947872162, -0.050056591629981995, 0.07467260956764221, -0.014318378642201424, 0.015226002782583237, -0.05207599326968193, -0.14729022979736328, -0.1511041224002838, -0.08141259849071503, 0.19194836914539337, -0.13579736649990082, 0.032806772738695145, -0.010206709615886211, -0.03503800928592682, -0.03982396423816681, 0.06577993929386139, 0.07988248765468597, -0.17642828822135925, -0.09677606076002121, -0.08474887907505035, -0.028476744890213013, 0.05401906371116638, -0.19066357612609863, 0.10490589588880539, 0.04826734960079193], "changes": {"1wk": -1.9386139809786909}}, {"text": "LIVE The latest news and updates on Trump's tariffs PREMIUM Arvinas, Pfizer Present 'Encouraging' Preliminary Data for Prospective Breast Cancer Treatment MT Newswires Tue, Dec 10, 2024, 6:05 PM 1 min read In This Article: PFE ARVN Arvinas (ARVN) and Pfizer (PFE) on Tuesday reported \"encouraging\" preliminary data from an ongoing p PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "ARVN", "date": "2024-12-10T18:05:08", "sentiment": {"score": 0.13502379693090916, "confidence": 0.14492088556289673, "probabilities": {"positive": 0.14492088556289673, "negative": 0.009897088631987572, "neutral": 0.8451820015907288}}, "embedding": [-0.10907978564500809, -0.11810790747404099, -0.052025455981492996, 0.0463566817343235, 0.21163097023963928, 0.013495254330337048, 0.07032059133052826, -0.000651011650916189, -0.19148147106170654, 0.03182860463857651, 0.0018298802897334099, 0.16076810657978058, -0.09484860301017761, -0.010209833271801472, -0.09139475971460342, 0.010938018560409546, 0.03532791882753372, -0.14954189956188202, 0.07399723678827286, 0.1021614521741867, -0.14200669527053833, -0.07605637609958649, 0.15921159088611603, 0.07168830186128616, -0.008862021379172802, 0.08310674875974655, -0.07866144180297852, 0.014677639119327068, -0.044925712049007416, -0.03711140528321266, 0.0016477953176945448, -0.08245744556188583, 0.05396916717290878, -0.03463802486658096, -0.02502509206533432, -0.07719552516937256, -0.07858528196811676, 0.1431097835302353, -0.09765487909317017, 0.009682321920990944, 0.18726558983325958, -0.31490036845207214, -0.21041318774223328, 0.1909279078245163, 0.06971145421266556, 0.03948035463690758, -0.018536867573857307, 0.08295919001102448, 0.039934296160936356, 0.05302392318844795, -0.146262064576149, -0.12998932600021362, 0.03708852455019951, -0.07254217565059662, 0.05202585458755493, -0.11217053234577179, -0.0764777734875679, -0.1493433564901352, -0.009654059074819088, -0.064088836312294, -0.10024063289165497, -0.15368574857711792, -0.1645086705684662, 0.13015684485435486, 0.04919843003153801, 0.057357337325811386, 0.031125294044613838, 0.11083351075649261, 0.018189996480941772, -0.017177989706397057, 0.03616316244006157, 0.08368436247110367, -0.03787170723080635, 0.12106344848871231, 0.017035257071256638, 0.0933445543050766, 0.24238388240337372, 0.030830437317490578, 0.21321506798267365, -0.0883442834019661, 0.025688746944069862, -0.11305470764636993, 0.06649427860975266, -0.010186409577727318, 0.05528521537780762, -0.1528775990009308, -0.12852346897125244, -0.09739110618829727, 0.002101612277328968, -0.12638132274150848, 0.19454891979694366, 0.011565874330699444, -0.03387748822569847, 0.12076719105243683, -0.18295864760875702, 0.023683372884988785, -0.14601664245128632, -0.05976630374789238, -0.16756175458431244, 0.04776076599955559, 0.006944025866687298, -0.028181105852127075, -0.08279955387115479, -0.037522997707128525, -0.12990416586399078, -0.14436320960521698, -0.1126253604888916, 0.05784976854920387, 0.10737207531929016, 0.23111560940742493, -0.07421180605888367, 0.04693149775266647, -0.022299841046333313, -0.10577375441789627, -0.017378639429807663, 0.0920807272195816, -0.060414545238018036, -0.12786805629730225, 0.09462419897317886, -0.024273701012134552, -0.06486300379037857, 0.121220164000988, -0.054514165967702866, 0.05174091458320618, 0.04433507099747658, 0.023466408252716064, -0.10872536897659302, 1.237128605308571e-32, 0.004640749655663967, 0.08552372455596924, 0.10143975913524628, -0.057090938091278076, 0.003413949627429247, 0.14830239117145538, -0.0534617118537426, -0.23833344876766205, -0.08631090819835663, -0.050684310495853424, -0.15983885526657104, 0.22054971754550934, -0.07422441989183426, 0.09993898868560791, -0.08961587399244308, -0.1893698126077652, -0.08144964277744293, 0.23146648705005646, 0.09069410711526871, 0.0411515049636364, 0.11685927957296371, -0.07080840319395065, -0.05363745242357254, 0.06663257628679276, 0.09863404929637909, 0.1886487603187561, 0.0532863512635231, 0.008574428968131542, 0.09122653305530548, 0.07709804177284241, -0.1433054506778717, 0.09135560691356659, 0.07617003470659256, -0.09316512942314148, -0.13075076043605804, 0.017153048887848854, -0.1194302961230278, -0.11419139057397842, -0.08181655406951904, -0.10509137064218521, 0.04405929893255234, -0.05086827278137207, 0.08237286657094955, 0.0822497308254242, 0.03240055963397026, -0.09708987921476364, -0.07262294739484787, -0.024020563811063766, 0.0037472520489245653, -0.0958610400557518, -0.08340533077716827, -0.0020126907620579004, -0.1432839035987854, -0.05814880132675171, -0.07926592975854874, 0.045592375099658966, -0.1350376456975937, -0.07336250692605972, 0.16190385818481445, -0.1425880789756775, 0.27240997552871704, 0.07971181720495224, 0.06499435752630234, -0.028222769498825073, -0.10037408024072647, 0.14353807270526886, -0.0840054526925087, -0.07268480211496353, -0.1040751039981842, 0.17239731550216675, 0.08527906984090805, 0.007418356370180845, 0.08493706583976746, -0.08178410679101944, -0.012076237238943577, 0.09178754687309265, -0.09482541680335999, 0.09045201539993286, 0.10048551857471466, -0.0011674154084175825, -0.056229669600725174, -0.0841599777340889, 0.1511802077293396, 0.15571261942386627, 0.06631551682949066, 0.01891005039215088, 0.021102122962474823, 0.04384031519293785, -0.010586841031908989, 0.01838085614144802, -0.0030511391814798117, 0.03667241707444191, -0.045041415840387344, 0.014655889943242073, -0.040267594158649445, -1.4644900777823285e-32, -0.07733537256717682, 0.021012887358665466, 0.04166989400982857, -0.03931142017245293, -0.03345241770148277, 0.003262811340391636, -0.002599692437797785, 0.03485895320773125, 0.2546907365322113, 0.06108890473842621, 0.013480005785822868, -0.05754219368100166, -0.058112338185310364, -0.02146424725651741, -0.018067335709929466, -0.02668183110654354, 0.13312380015850067, -0.0497148334980011, -0.10630752146244049, -0.037291523069143295, -0.045549653470516205, 0.1675015091896057, -0.17214816808700562, 0.2428721934556961, -0.07772930711507797, -0.08384580910205841, 0.19950591027736664, 0.03875454142689705, 0.019184453412890434, -0.19544725120067596, -0.14167065918445587, -0.06518619507551193, -0.16236035525798798, 0.050827205181121826, -0.0876365378499031, -0.033958252519369125, 0.1857529878616333, 0.07354660332202911, 0.02242567390203476, -0.021564144641160965, 0.18993109464645386, -0.010754097253084183, -0.21796172857284546, -0.0033296376932412386, -0.011792857199907303, 0.016961732879281044, -0.010014163330197334, 0.009397132322192192, 0.03691527992486954, -0.08254590630531311, -0.05860969051718712, 0.15548977255821228, -0.00041648410842753947, 0.11790599673986435, -0.19014617800712585, -0.019478540867567062, 0.02459247037768364, -0.0035917789209634066, 0.0030880081467330456, 0.07252185046672821, -0.0233901534229517, 0.11234191805124283, -0.20685891807079315, -0.04413144290447235, 0.031900130212306976, 0.061435963958501816, 0.07243606448173523, -0.09259528666734695, 0.1510089635848999, -0.04079469293355942, 0.02645309828221798, -0.06565013527870178, -0.11539369076490402, -0.043057091534137726, 0.051714856177568436, 0.11796867102384567, 0.07447762787342072, -0.010596103966236115, -0.03555725887417793, 0.08283069729804993, 0.1818358302116394, -0.14511515200138092, 0.002905544824898243, -0.025899387896060944, 0.057479143142700195, -0.09115242958068848, 0.14012114703655243, -0.06128211319446564, -0.07121653109788895, 0.0623859241604805, -0.2048613429069519, -0.1536792665719986, -0.19115455448627472, 0.0668119341135025, -0.05723929405212402, -1.0030331765165101e-07, 0.15206803381443024, -0.001810884103178978, 0.09076467156410217, 0.05806010216474533, 0.046153511852025986, 0.013506761752068996, -0.1432705670595169, -0.05847753584384918, -0.09831520169973373, 0.04907555133104324, 0.1118447557091713, 0.041737623512744904, -0.041431017220020294, -0.08576788008213043, 0.08714889734983444, 0.02144402451813221, 0.14889729022979736, 0.08354513347148895, -0.033964719623327255, -0.08390433341264725, -0.07155188173055649, 0.19707687199115753, -0.0903211161494255, -0.06074974313378334, 0.10776922851800919, 0.13945423066616058, -0.0856834426522255, 0.017770856618881226, 0.10204491764307022, 0.04181462898850441, -0.057618893682956696, -0.03986414894461632, -0.046925827860832214, 0.031012127175927162, -0.026967138051986694, 0.08549496531486511, 0.0836729034781456, -0.0962696522474289, 0.10084633529186249, 0.01489883940666914, -0.03995140641927719, -0.07883217930793762, 0.058845411986112595, 0.018874572589993477, -0.14295242726802826, 0.07384881377220154, -0.16709309816360474, -0.2144927680492401, 0.1728401780128479, 0.0663042962551117, 0.07445898652076721, -0.041420452296733856, 0.16131724417209625, -0.09679041057825089, -0.01617884822189808, 0.11216045916080475, 0.002645371947437525, -0.19478560984134674, -0.03291340544819832, 0.10130622982978821, 0.2952057719230652, -0.2751713693141937, 0.04013148322701454, 0.20344984531402588], "changes": {"1wk": -22.326147771659887, "1mo": -19.398131062075937}}, {"text": "LIVE The latest news and updates on Trump's tariffs Why Is Arvinas, Inc. (ARVN) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds? Laiba Immad Wed, Dec 4, 2024, 9:19 PM 6 min read In This Article: ARVN We recently compiled a list of the 10 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds . In this article, we are going to take a look at where Arvinas, Inc. (NASDAQ:ARVN) stands against the other small-cap biotech stocks. Revolutionizing Healthcare and Economy: The Rapid Growth of Biotechnology The biotechnology sector is expanding quickly due to rising demand for novel therapies, technological advances, and government assistance. Advances in fields like gene editing, sequencing, personalized medicine, and artificial intelligence are making new techniques possible, while the aging population and growing healthcare demands are driving a robust market for new treatments. According to a report by McKinsey & Company, venture capital firms made approximately $52 billion in global investments in therapeutic-focused biotech companies between 2019 and 2021. Two-thirds of this sum was given to platform-tech start-up companies. Despite its growth, many biotech companies have faced challenges in turbulent markets, taking drastic measures such as cutting programs and implementing significant layoffs to conserve cash. While recent rate cuts could encourage the revival of scientific projects, analysts like Jared Holz note the difficulty of gauging their impact. Holz also highlighted a shift in market dynamics, observing that biotech's performance increasingly correlates with small-cap equities. If small-cap stocks trade well, biotech is likely to follow, though stagnation could occur if momentum fades. Notably, the idea of interest rates predicting biotech success is relatively new, emerging only after the pandemic, which reshaped the industry by driving substantial investment into therapeutic-focused companies. With innovative treatments, biotech businesses are revolutionizing healthcare by tackling important unmet medical needs. Establishing the National Bioeconomy Board as a component of Biden's Investing in America agenda is a significant breakthrough. It seeks to maximize biotechnology's economic potential in the United States. Furthermore, policy suggestions to expedite the approval process for biotechnology goods are being developed by the National Security Commission on Emerging Biotechnology. More academics will be able to use biotechnology for agricultural purposes if entry obstacles are reduced, which will benefit American farmers and increase food security. It is anticipated that these initiatives will open up new markets. Pharmaceuticals as Defensive Investments and the 2024 Healthcare Market Outlook This year (2024) started strongly for the biotechnology sector due to a rise in mergers and acquisitions as well as anticipations of falling interest rates. Therefore, estimates suggest that the worldwide biotechnology market might increase at a compound annual growth rate (CAGR) of around 14% from 2024 to 2033, reaching an astonishing $5.7 trillion. The market for agricultural biotechnology is also expected to develop at a 7.9% compound annual growth rate (CAGR) and reach $232 billion by 2032. Story Continues But even with the market's potential, investing in biotech companies still carries a number of serious dangers. Bankruptcy may result from failing to satisfy clinical trial endpoints or obtain adequate finance before a product launch. In the biotech industry, where drug development usually takes more than ten years and has an estimated failure rate of about 90%, the danger of failure is very substantial. Hence, biotech stocks are often considered \u201chigh-risk, high-reward\u201d investments due to their upside potential coupled with significant risks Our Methodology In our methodology, we identified the top small-cap biotech stocks with significant growth potential, ranked according to their total hedge fund holdings as of Q2 2024. Our selection process began by filtering companies with a small market capitalization. Next, we reviewed analyst recommendations, focusing on stocks with strong bullish sentiment and high institutional ownership. Finally, we ranked these companies based on the number of hedge funds holding their shares as of Q2 2024. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points ( see more details here ). A biopharma executive in a meeting room discussing the clinical-stage of a new therapy. Arvinas, Inc. (NASDAQ: ARVN ) Number of Hedge Fund Holdings: 34 Arvinas, Inc. (NASDAQ:ARVN) is a clinical-stage biopharmaceutical company that specializes in developing innovative protein degradation therapeutics. At its core, the company focuses on creating drugs that harness the body's natural protein disposal system to selectively remove disease-causing proteins. A major catalyst for Arvinas, Inc. (NASDAQ:ARVN) is its robust clinical pipeline, particularly its lead candidate vepdegestrant (ARV-471). This PROTAC protein degrader is being investigated for treating ER+/HER2- breast cancer. Clinical trials have yielded encouraging results, with a Phase 1b trial demonstrating a clinical benefit rate of 63% and an overall response rate of 41.9% among heavily pretreated patients. These outcomes have prompted the initiation of several Phase 3 trials, including VERITAC-2 and VERITAC-3, which could pave the way for regulatory approval if successful. The company has shown impressive growth since its market debut in 2016, when it raised about $120 million through the issuance of approximately 7.5 million shares at $16 per share. The stock has experienced significant volatility, with notable gains in recent years. For instance, shares surged from around $22 in November 2023 to approximately $29, marking an impressive gain of nearly 35%. Arvinas, Inc. (NASDAQ:ARVN) has emerged as one of the best biotech stocks, gaining notable hedge fund interest. The company reported impressive Q3 2024 financial results, with revenue surging to $102.4 million from $34.6 million in Q3 2023 which was driven primarily by $76.7 million from the Novartis license agreement, which offset declines in collaborations with Pfizer and Bayer. The corporation maintains a strong cash position of $1.1 billion, ensuring an operational runway into 2027. R&D expenses rose slightly to $86.9 million from $85.9 million, while G&A expenses increased significantly to $75.8 million from $22.6 million, reflecting strategic investments. As of Q3 2024, 34 hedge funds held stakes in Arvinas, Inc. (NASDAQ:ARVN), with EcoR1 Capital being the largest shareholder, holding $165.7 million in the company, according to the Insider Monkey database. Analysts have a consensus Strong Buy rating on the company, with an average price target of $61.14, ranging from a low of $48.00 to a high of $87.00. This represents a potential upside of 144.85% from the current price of $24.97. Overall ARVN ranks 3rd on our list of the best small-cap biotech stocks with massive potential according to hedge funds. While we acknowledge the potential of ARVN as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than ARVN but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock . READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock Disclosure: None. This article is originally published at Insider Monkey . View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "ARVN", "date": "2024-12-04T21:19:17", "sentiment": {"score": 0.650337366387248, "confidence": 0.6693362593650818, "probabilities": {"positive": 0.6693362593650818, "negative": 0.018998892977833748, "neutral": 0.311664879322052}}, "embedding": [0.028575574979186058, -0.17040112614631653, -0.00048794597387313843, -0.06593183428049088, 0.1007397472858429, 0.012117162346839905, 0.0019208034500479698, 0.10764569044113159, 0.08702442049980164, 0.10010891407728195, -0.12597504258155823, 0.13746953010559082, -0.10102567821741104, 0.019623197615146637, -0.1844942569732666, 0.004573030397295952, -0.09013749659061432, -0.018218452110886574, -0.09329060465097427, 0.1354573518037796, -0.028621993958950043, -0.0007747509516775608, 0.030290845781564713, 0.018521113321185112, 0.008330521173775196, -0.034785300493240356, -0.06435251235961914, -0.10571923851966858, -0.26247552037239075, -0.04621174558997154, 0.09054923057556152, 0.12424564361572266, 0.042542796581983566, -0.05089779198169708, 0.025387629866600037, 0.11454211175441742, -0.10050000250339508, 0.09889204800128937, 0.12205973267555237, -0.01847388595342636, 0.062091320753097534, -0.13906385004520416, -0.1186167448759079, 0.09390467405319214, 0.12187661230564117, -0.10146785527467728, 0.003468453651294112, -0.04999755695462227, 0.07195013016462326, -0.03674883022904396, -0.20487365126609802, -0.1731964349746704, 0.018317455425858498, -0.07180381566286087, -0.05864807963371277, -0.014272570610046387, -0.06172053888440132, -0.06265928596258163, 0.053768035024404526, 0.05325111001729965, 0.05800838768482208, -0.10794986039400101, 0.07074436545372009, -0.03383997455239296, 0.0805751234292984, -0.08725187182426453, 0.08992816507816315, 0.12065514922142029, -0.06911022961139679, 0.0670783668756485, 0.15859058499336243, -0.05896417051553726, -0.1280350387096405, 0.10315849632024765, -0.07318432629108429, 0.11225991696119308, 0.11056794971227646, 0.21713975071907043, 0.24824479222297668, -0.060974933207035065, 0.05104638636112213, -0.09553582221269608, 0.01101063285022974, -0.020913459360599518, -0.1500278115272522, 0.013961154967546463, 0.03730816766619682, 0.06731784343719482, 0.10484907776117325, 0.017547987401485443, -0.006477362476289272, -0.03886806592345238, 0.06500115990638733, 0.04045753926038742, 0.08426156640052795, -0.04102497547864914, -0.039801985025405884, -0.02390749752521515, 0.020421786233782768, 0.03738393262028694, 0.053676627576351166, -0.019612975418567657, -0.03579030558466911, -0.0054540811106562614, -0.03851901739835739, -0.06617087870836258, -0.01188364252448082, -0.0990954339504242, 0.14420267939567566, 0.10707418620586395, -0.10049089789390564, 0.1286204755306244, -0.09802539646625519, 0.066447913646698, -0.09940532594919205, 0.15012440085411072, 0.0036912192590534687, -0.06404375284910202, 0.10833355784416199, 0.01947018876671791, -0.0022507663816213608, 0.07015383988618851, -0.05397620052099228, -0.16198953986167908, -0.11429299414157867, 0.09801094233989716, -0.17099952697753906, 9.197023719795422e-33, -0.06296955794095993, 0.0607595331966877, 0.006491927430033684, 0.01062343455851078, -0.06972113251686096, -0.0038944659754633904, -0.00381224462762475, -0.065993532538414, -0.18921786546707153, -0.10235431045293808, -0.1766379475593567, 0.07881031930446625, -0.03822581470012665, 0.10215997695922852, 0.014015678316354752, -0.1916942298412323, -0.03330278396606445, 0.07157733291387558, 0.0379909873008728, -0.07100001722574234, -0.12000459432601929, -0.004194209352135658, -0.07665672898292542, 0.05846761539578438, 0.027367008849978447, -0.17556235194206238, -0.07827048003673553, -0.050751253962516785, 0.08874694257974625, 0.07672569155693054, -0.10320313274860382, 0.12710486352443695, -0.01174638420343399, -0.07809394598007202, -0.03137144073843956, -0.09265313297510147, -0.07491487264633179, -0.11323206126689911, 0.09179716557264328, 0.1244470402598381, -0.07347890734672546, 0.14791926741600037, -0.07040466368198395, -0.03175879269838333, 0.012090010568499565, 0.0578327476978302, 0.010003816336393356, 0.06558148562908173, -0.07477863878011703, -0.00036505982279777527, -0.1182444617152214, 0.10604545474052429, 0.07506163418292999, -0.12547148764133453, 0.07375558465719223, -0.006655512377619743, -0.18881258368492126, -0.12200209498405457, 0.029288537800312042, -0.008038622327148914, -0.013101048767566681, 0.06383416801691055, -0.00017180421855300665, 0.13567715883255005, -0.11903651058673859, 0.20855452120304108, 0.09648235142230988, 0.11567360162734985, -0.06929554790258408, 0.23587539792060852, 0.06557989120483398, -0.11783137917518616, 0.000369025394320488, -0.06168895587325096, 0.01862046867609024, -0.028712131083011627, -0.03637130185961723, 0.07962869107723236, -0.053412459790706635, 0.058218859136104584, 0.03680232912302017, 0.024321766570210457, -0.13708928227424622, 0.04078109189867973, 0.007140275090932846, 0.0035001947544515133, 0.023498695343732834, 0.11257962882518768, 0.00497928261756897, -0.024428563192486763, -0.06902966648340225, -0.05159105360507965, -0.0035226233303546906, 0.11408381909132004, -0.009205643087625504, -1.0115081869051751e-32, -0.01781434565782547, -0.07696756720542908, -0.0010494720190763474, 0.04178939759731293, -0.004994604270905256, 0.009251002222299576, 0.10393727570772171, -0.12088228017091751, 0.037203267216682434, -0.06663351505994797, -0.008736761286854744, 0.05839613080024719, -0.006833791267126799, 0.003558102063834667, -0.1488875150680542, -0.00844678282737732, -0.007562297862023115, -0.104916512966156, 0.05073363333940506, -0.035259049385786057, 0.07836267352104187, 0.057092711329460144, -0.15017080307006836, 0.09800984710454941, -0.012727230787277222, 0.06047655642032623, -0.09465785324573517, 0.12416672706604004, 0.014464307576417923, -0.08512742817401886, -0.09517407417297363, 0.00931762345135212, -0.2020857334136963, 0.14241985976696014, -0.04778030514717102, 0.07872233539819717, 0.054721809923648834, -0.15495285391807556, 0.052038952708244324, -0.05186982452869415, 0.14296779036521912, -0.061502836644649506, -0.0950029045343399, 0.03257264941930771, 0.0053479354828596115, -0.06044016778469086, -0.024948764592409134, 0.09803164005279541, 0.14314797520637512, -0.040459051728248596, -0.0015148576349020004, 0.11430539190769196, 0.07457072287797928, -0.027629591524600983, -0.1607542634010315, -0.008242253214120865, 0.07360406965017319, 0.0389123372733593, -0.12592163681983948, 0.05035623535513878, 0.02856210246682167, 0.030893977731466293, 0.01955888792872429, 0.02587125264108181, -0.08165116608142853, -0.008503795601427555, 0.10345591604709625, 0.012983548454940319, -0.08646545559167862, -0.1355653703212738, 0.06435286998748779, -0.037632979452610016, 0.07592310756444931, -0.030079711228609085, -0.03449500352144241, 0.21186339855194092, 0.005024312064051628, -0.13353365659713745, -0.09559331834316254, 0.037934139370918274, 0.09063615649938583, -0.016054630279541016, 0.03396645188331604, -0.05446520820260048, -0.013666494749486446, 0.12964960932731628, -0.04739668220281601, -0.048221468925476074, -0.10816065967082977, 0.03169172257184982, -0.1388348937034607, -0.19554194808006287, -0.02976256236433983, 0.08048710972070694, -0.052829403430223465, -1.0043999054687447e-07, 0.18947654962539673, -0.11029131710529327, 0.1037617027759552, -0.08601611107587814, 0.04694712907075882, -0.02921547368168831, -0.13268649578094482, 0.09467042982578278, 0.10673392564058304, 0.1840025782585144, 0.04507067799568176, 0.19658678770065308, -0.12433144450187683, 0.20285914838314056, -0.04568066447973251, 0.08768948167562485, -0.1278597116470337, 0.06172621250152588, -0.03837182745337486, -0.03702222928404808, -0.02814676985144615, 0.15852496027946472, -0.0005418304353952408, 0.0008662506006658077, 0.051174990832805634, -0.07889703661203384, 0.013896333985030651, 0.03407258912920952, -0.022009260952472687, 0.016376202926039696, 0.019985951483249664, -0.05937037244439125, 0.039463017135858536, 0.04142169654369354, -0.01606624945998192, -0.03888469189405441, 0.008546972647309303, 0.011236321181058884, 0.018330153077840805, 0.019279319792985916, -0.013918633572757244, 0.009249923750758171, -0.03350239247083664, -0.05486081540584564, -0.06231839954853058, -0.11874446272850037, -0.09011852741241455, 0.0886719673871994, 0.12409576028585434, -0.09268476068973541, 0.0728151947259903, 0.014267055317759514, 0.059994135051965714, -0.009399776346981525, 0.014339654706418514, 0.15693026781082153, -0.062273237854242325, -0.03782553970813751, -0.07840095460414886, -0.040164556354284286, 0.031554240733385086, -0.2618113160133362, 0.1213926374912262, 0.04857557266950607], "changes": {"1wk": -11.224885949713906, "1mo": -19.259549063408414}}, {"text": "LIVE The latest news and updates on Trump's tariffs Arvinas, Inc. (ARVN): This Small-Cap Stock Is Ready To Explode Talha Qureshi Tue, Nov 19, 2024, 5:06 PM 6 min read In This Article: ARVN ^RUT We recently compiled a list of the 10 Best Small-Cap Stocks Ready To Explode . In this article, we are going to take a look at where Arvinas, Inc. (NASDAQ:ARVN) stands against the other small-cap stocks. Prospects For Extended Outperformance Of Small-Cap Stocks On October 7, Chuck Royce, founder and Senior Advisor, and Francis Gannon, Co-Chief Investment Officer and Managing Director of Royce Investment, discussed the outperformance of small-cap stocks. While discussing the reasons that led to the Russell 2000 Index doing well in Q3 '24, Gannon noted that the strong performance of the Russell 2000 Index, which was up 9.3%, in the third quarter of 2024 can be attributed to a \"quintessential reversion to the mean,\" as small-caps had lagged behind larger companies for an extended period. He thinks that the rebound was not surprising given the historical trends, as the small-cap index outperformed the large-cap Russell 1000, up 6.1%, and the mega-cap Russell Top 50, up 4.2% during this time. Read Also: 7 Best Nano Cap Stocks To Invest In and 10 High Growth Non-Tech Stocks That Are Profitable in 2024 . On the other hand, Royce mentioned that he was surprised by the concentration of the small-cap gains. He noted that all the gains for the quarter were compressed at the start, as by early July 16, the index had already achieved a 10.6% increase from the end of June, marking its high for the quarter. Royce further mentioned that this rapid ascent was followed by a notable decline, with the index dropping 10.1% from July 16 to August 7 before recovering most of its losses by the end of September. Despite this volatility, he expressed satisfaction with the small-cap performance overall for the quarter, especially since it marked a reversal after small-caps last outperformed large-caps in Q4 2023. Building further upon the volatility of small-cap stocks, Royce expressed that while volatility in small-cap stocks can be concerning, it is a normal part of investing in this asset class. He emphasized that they welcome volatility as it allows them to take advantage of price fluctuations for long-term gains. Historically, significant intra-year declines are common for small-caps, with the Russell 2000 experiencing double-digit pullbacks in 22 out of the last 25 years. While answering how the sector can sustain its market leadership performance, Gannon highlighted that market breadth among large caps often leads to better performance for small caps. He pointed out that when the equal-weighted Russell 1000 outperformed its capitalization-weighted counterpart, small-caps typically led in performance. This trend suggests that an expansion of returns across different sectors is a positive indicator for small-cap stocks. Story Continues Moreover, both Royce and Gannon stressed that earnings growth is crucial for the long-term success of small-cap stocks. Gannon stated that while short-term market psychology can influence stock prices, consistent earnings are fundamental for sustaining long-term performance. He noted that despite a significant portion of small-cap companies lacking earnings, around 44.6%, those with earnings are expected to grow faster than their large-cap counterparts in 2025. Our Methodology To curate the list of 10 best small-cap stocks ready to explode we used the Finviz stock screener and CNN. Using the screener we shortlisted small-cap stocks (market-cap between $500 million to $2 billion) for which analysts are expecting more than 50% upside from the current stock price. Once we had shortlisted the stocks we cross-checked the analysts' upside potential from CNN. Lastly, we ranked the stocks based on the ascending order of the analyst upside potential. Please note that the data was recorded on November 15, 2024. Why do we care about what hedge funds do? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter\u2019s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points ( see more details here ). A biopharma executive in a meeting room discussing the clinical-stage of a new therapy. Arvinas, Inc. (NASDAQ: ARVN ) Analyst Upside Potential: 166.90% Arvinas, Inc. (NASDAQ:ARVN) is a clinical-stage biotechnology company that ranks 4th on our list of 10 best small-cap stocks ready to explode. Analysts\u2019 12-month median price target for the stock is presenting a 166.90% upside from current levels. The company engages in developing treatments for patients with cancer and other neurodegenerative disorders. The company uses a special technology called PROTAC (proteolysis-targeting chimeras). This technology helps the body\u2019s systems to identify and eliminate disease-causing proteins more effectively. Several products of Arvinas, Inc. (NASDAQ:ARVN) including ARV-471, ARV-766, and ARV-102 are at different stages of their clinical trials. The company made significant progress in its drug development efforts and reported positive developments across its drug portfolio during the third quarter of 2024. For instance, it is on track to release important results from a major clinical trial (VERITAC-2) for breast cancer treatment by late 2024 or early 2025. Moreover, they are also working closely with Pfizer to potentially change how ER+/HER2- breast cancer is treated, indicating a promising partnership aimed at improving patient care. Looking ahead, Arvinas, Inc. (NASDAQ:ARVN) plans to complete patient enrollment for several trials by the end of 2024 and expects to share data from these studies in 2025. Management is also preparing to start new combination trials for breast cancer treatments. Financially speaking, the company generated $102.4 million in revenue during the quarter, a substantial increase from $34.6 million in the same quarter of 2023. The revenue growth was driven by a notable contribution of $76.7 million from a licensing agreement with Novartis. Overall ARVN ranks 1st on our list of the best small-cap stocks to buy. While we acknowledge the potential of ARVN as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter timeframe. If you are looking for a promising AI stock that trades at less than 5 times its earnings, check out our report about the cheapest AI stock . READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock . Disclosure: None. This article is originally published at Insider Monkey . View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "ARVN", "date": "2024-11-19T17:06:07", "sentiment": {"score": -0.7356583997607231, "confidence": 0.8551614880561829, "probabilities": {"positive": 0.11950308829545975, "negative": 0.8551614880561829, "neutral": 0.025335410609841347}}, "embedding": [-0.05695201829075813, -0.01202037651091814, 0.039467182010412216, 0.09279576689004898, 0.1066259816288948, 0.03357136994600296, 0.08936963230371475, 0.15801279246807098, -0.023010239005088806, -0.004295731894671917, -0.026988741010427475, 0.17723585665225983, 0.004032624885439873, -0.04651153087615967, -0.18810218572616577, -0.03700203448534012, -0.09120141714811325, -0.020986929535865784, -0.15857678651809692, 0.005186229012906551, -0.17732129991054535, -0.030773190781474113, -0.03857846185564995, -0.04040496423840523, 0.10939273983240128, 0.00974735151976347, -0.07520343363285065, 0.03641163185238838, -0.10592822730541229, -0.11357752978801727, -0.08233849704265594, 0.09567400813102722, 0.06020825356245041, -0.006907117553055286, -0.16343361139297485, 0.04719017446041107, 0.07081723213195801, 0.12532249093055725, 0.12187081575393677, -0.018038183450698853, 0.059795454144477844, 0.034959301352500916, -0.06078702583909035, -0.041210610419511795, -0.02168169617652893, -0.0638783797621727, 0.040442004799842834, -0.08767364919185638, -0.006795658264309168, -0.08108742535114288, -0.13083818554878235, 0.010194218717515469, 0.021727491170167923, -0.06540965288877487, -0.09673071652650833, 0.06786072254180908, -0.11634901911020279, -0.05902846157550812, 0.12779143452644348, 0.03937705606222153, 0.060572490096092224, -0.03232395648956299, 0.05701062083244324, -0.037766024470329285, 0.1891888529062271, -0.05120362713932991, 0.15874651074409485, 0.00837835855782032, -0.09797264635562897, 0.07844831049442291, 0.12797188758850098, 0.0038776355795562267, -0.2823370397090912, -3.8370490074157715e-06, -0.06985063850879669, 0.011677789501845837, 0.07766497880220413, 0.000606931746006012, 0.07171672582626343, 0.07087095826864243, -0.11232519149780273, -0.010576063767075539, -0.09883084148168564, -0.13078837096691132, -0.17113089561462402, -0.04578089714050293, 0.0027470681816339493, -0.07958100736141205, 0.0886041671037674, 0.030365046113729477, 0.10282358527183533, 0.0692678764462471, -0.060409244149923325, 0.023430507630109787, 0.16629447042942047, 0.0097421295940876, 0.028498468920588493, 0.006327507551759481, -0.010251764208078384, 0.0909782275557518, 0.20581141114234924, 0.16911199688911438, -0.10553623735904694, -0.0824357271194458, 0.032283030450344086, -0.09078703075647354, 0.14806531369686127, -0.10590895265340805, -0.10141415894031525, 0.024609636515378952, -0.048605822026729584, 0.08316393196582794, -0.11028321087360382, -0.20056220889091492, -0.13438916206359863, 0.08464637398719788, -0.035353586077690125, 0.01963651552796364, 0.008681626059114933, -0.028982413932681084, -0.0480213388800621, 0.24009719491004944, -0.03906622529029846, -0.06808272004127502, 0.028792310506105423, 0.12173665314912796, -0.11546541750431061, 5.8317828600888676e-33, -0.012265264987945557, 0.09715572744607925, -0.09244894236326218, 0.08334436267614365, -0.10746100544929504, 0.030326228588819504, 0.008506263606250286, -0.0061812009662389755, -0.15938004851341248, -0.044922102242708206, -0.06001076102256775, 0.18499420583248138, -0.060596317052841187, -0.16195741295814514, 0.11321595311164856, -0.10598523169755936, 0.0491025447845459, 0.05418223887681961, -0.05484416335821152, -0.18662074208259583, -0.003212383482605219, 0.04563138633966446, -0.0011556304525583982, -0.00763876223936677, 0.04812179505825043, 0.02718224562704563, 0.024033091962337494, -0.10611697286367416, -0.024051450192928314, 0.07238274067640305, -0.04664071649312973, 0.198256716132164, -0.1006472036242485, -0.09774371981620789, 0.009032371453940868, -0.028217054903507233, -0.15697947144508362, -0.0638083666563034, 0.04974212497472763, -0.06949147582054138, -0.019608646631240845, 0.1754201054573059, -0.0367632620036602, -0.09854617714881897, -0.12424445897340775, 0.020238816738128662, -0.0019073477014899254, 0.09386973083019257, 0.04587595909833908, -0.0021796831861138344, -0.026013415306806564, -0.027862174436450005, 0.027381781488656998, -0.011406591162085533, -0.04478738084435463, 0.09779644012451172, 0.009946851991117, -0.06001632288098335, 0.057170964777469635, 0.13072402775287628, 0.03471878170967102, 0.11842035502195358, -0.07047723978757858, 0.1557789146900177, -0.19166015088558197, 0.18641436100006104, -0.009350206702947617, 0.11174483597278595, -0.1160549446940422, 0.18377351760864258, 0.1256428360939026, -0.08961810171604156, 0.08812956511974335, -0.06955628097057343, 0.1457829475402832, -0.06948749721050262, -0.009219489060342312, -0.04276108369231224, -0.004515594802796841, -0.06624290347099304, 0.020517390221357346, -0.05757759511470795, 0.13042597472667694, -0.09724990278482437, -0.04694392532110214, -0.08552328497171402, 0.13464879989624023, 0.07384893298149109, 0.04929929971694946, -0.00831535179167986, 0.029873928055167198, -0.02394900657236576, 0.04215853661298752, -0.0768631100654602, -0.06499762833118439, -6.658573056553462e-33, -0.021067211404442787, -0.07351250946521759, -0.008587831631302834, -0.032228417694568634, -0.04665420949459076, 0.010798870585858822, 0.13981139659881592, 0.010908442549407482, -0.11538559198379517, -0.104839988052845, 0.02727903425693512, 0.053583189845085144, -0.03599492460489273, 0.012105509638786316, -0.06062677502632141, -0.0783059298992157, 0.11829609423875809, -0.12867428362369537, 0.08476483821868896, -0.05311676859855652, 0.1382434070110321, 0.04311482608318329, -0.15762171149253845, 0.1276693493127823, -0.022577490657567978, -0.0282833743840456, 0.014986925758421421, 0.08036977797746658, -0.07495306432247162, -0.03495832905173302, -0.017980802804231644, -0.050871334969997406, -0.034425053745508194, 0.24617743492126465, 0.04534297436475754, 0.05259134620428085, 0.045629311352968216, -0.13324660062789917, -0.0749550387263298, 0.06297969818115234, 0.03655484318733215, -0.010969596914947033, 0.03276391327381134, 0.029333431273698807, 0.046736426651477814, 0.04597421735525131, 0.034112293273210526, -0.009522581472992897, 0.11590271443128586, 0.010214138776063919, 0.06879406422376633, 0.07496555149555206, -0.014306407421827316, 0.1994362771511078, -0.11240872740745544, 0.08758185803890228, -0.05194653943181038, 0.09304600208997726, -0.06442518532276154, 0.008317341096699238, -0.05868024379014969, 0.019163697957992554, 0.033945538103580475, -0.07716536521911621, 0.0061052944511175156, -0.08068981766700745, -0.06876224279403687, -0.19793309271335602, -0.05532345175743103, -0.19165939092636108, 0.036504894495010376, -0.12531498074531555, 0.13912169635295868, -0.09541758894920349, -0.11656897515058517, 0.16963769495487213, -0.003925523720681667, -0.010739516466856003, -0.04856281355023384, -0.01422559842467308, -0.03464416787028313, 0.1134335994720459, -0.026759108528494835, 0.04987107962369919, 0.0073662325739860535, 0.11823944747447968, 0.010959628038108349, -0.06799174845218658, -0.08137309551239014, 0.07520139962434769, -0.07107716053724289, -0.1297997236251831, 0.003386571304872632, 0.046656087040901184, -0.051074013113975525, -9.959310887097672e-08, 0.04267833009362221, 0.021167835220694542, -0.029301561415195465, 0.06763678044080734, 0.08825521171092987, 0.07397029548883438, 0.020958751440048218, 0.057034872472286224, -0.015198026783764362, 0.17342707514762878, 0.1245952621102333, -0.0033924453891813755, -0.1294746696949005, 0.06206352263689041, -0.022526253014802933, 0.002725361380726099, -0.16748900711536407, -0.035407647490501404, -0.021198416128754616, -0.03922613710165024, 0.04057099297642708, 0.20627307891845703, 0.01836293376982212, -0.08839233219623566, -0.02686205878853798, 0.03053974360227585, -0.0014990561176091433, 0.11521777510643005, -0.07958818227052689, -0.022714246064424515, 0.11267022043466568, -0.021760815754532814, -0.02848653867840767, -0.04691893979907036, -0.005439282860606909, 0.13300789892673492, 0.056317031383514404, 0.12397954612970352, 0.0629948228597641, 0.03290719538927078, -0.021507741883397102, -0.04845065250992775, -0.020406212657690048, -0.01798476278781891, -0.04279911518096924, -0.05677736550569534, -0.23031362891197205, -0.0016896510496735573, 0.17185652256011963, -0.04097852110862732, 0.059898845851421356, -0.05320317670702934, 0.02735351398587227, 0.11869964003562927, 0.11629283428192139, 0.02456551045179367, -0.11585414409637451, -0.051961008459329605, -0.180515319108963, -0.03375011682510376, 0.13859599828720093, -0.17075249552726746, -0.03972560539841652, 0.19291263818740845], "changes": {"1wk": 16.21996454658338, "1mo": -14.001843182797336}}, {"text": "LIVE The latest news and updates on Trump's tariffs Arvinas-Pfizer Partner Cancer Drug Trial Shows 63% Clinical Benefit In Breast Cancer Patients Vandana Singh Tue, Dec 10, 2024, 9:23 PM 2 min read In This Article: ARVN PFE Arvinas-Pfizer Partner Cancer Drug Trial Shows 63% Clinical Benefit In Breast Cancer Patients On Tuesday, Arvinas Inc . (NASDAQ: ARVN ) and Pfizer Inc. (NYSE: PFE ) announced preliminary data from the ongoing Phase 1b portion of the TACTIVE-U sub-study of vepdegestrant in combination with abemaciclib for locally advanced or metastatic estrogen receptor-positive/human epidermal growth factor receptor 2 negative breast cancer. These data will be presented at the 2024 San Antonio Breast Cancer Symposium. Preliminary results from 16 patients in the Phase 1b sub-study demonstrated a tolerable safety profile for the combination of abemaciclib 150 mg twice daily (BID) with the recommended Phase 3 monotherapy dose of vepdegestrant (200mg once daily; QD). An encouraging clinical benefit rate of 62.5% was observed among patients with both mutant ESR1 and wild-type ESR1 disease who had all been previously treated with a CDK4/6 inhibitor. Pharmacokinetic data demonstrated no significant drug-drug interaction between vepdegestrant and abemaciclib, and no clinically meaningful effect on abemaciclib exposure was observed. In addition to tolerability, the results demonstrated a safety profile consistent with the known properties of abemaciclib and observed data in other clinical trials for vepdegestrant. These findings support the ongoing Phase 2 portion of the study, which is evaluating full dose abemaciclib (150mg BID) in combination with vepdegestrant (200 mg QD) in post-CDK4/6 advanced breast cancer. Additional details on the TACTIVE-U poster presentation at SABCS are below: Key findings included: There was no significant drug-drug interaction, and data reflected vepdegestrant has no clinically meaningful effect on abemaciclib exposure. Encouraging preliminary antitumor activity is observed with a clinical benefit rate of 62.5% in all CBR-eligible patients (10/16), 62.5% in patients with mutant ESR1 (5/8), and 62.5% in patients with wild-type ESR1 (5/8). The objective response rate (ORR) in evaluable patients was 26.7% overall (4/15), 37.5% in patients with mutant ESR1 (3/8), and 14% in patients with wild-type ESR1 (1/7). Arvinas and Pfizer continue to evaluate data from the ongoing TACTIVE-U clinical trial, including combinations of vepdegestrant plus abemaciclib, ribociclib, or samuraciclib. Price Action: At the last check on Tuesday, PFE stock was down 1.70% at $25.66, and ARVN stock was down 1.30% at $24.76. Read Next: What\u2019s Going On With Eli Lilly Stock On Tuesday? Photo by Aunt Spray via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily , plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Story Continues Get the latest stock analysis from Benzinga? PFIZER (PFE): Free Stock Analysis Report This article Arvinas-Pfizer Partner Cancer Drug Trial Shows 63% Clinical Benefit In Breast Cancer Patients originally appeared on Benzinga.com \u00a9 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "ARVN", "date": "2024-12-10T21:23:07", "sentiment": {"score": 0.08508445508778095, "confidence": 0.10711851716041565, "probabilities": {"positive": 0.10711851716041565, "negative": 0.022034062072634697, "neutral": 0.8708474636077881}}, "embedding": [0.04511984437704086, -0.15900643169879913, -0.05718741938471794, -0.1062060296535492, 0.09819681197404861, -0.14237354695796967, -0.092786505818367, 0.19846777617931366, 0.03807387501001358, 0.0014552464708685875, -0.0771065205335617, 0.02846883051097393, 0.05337706580758095, 0.018879691138863564, 0.009712042286992073, 0.18578286468982697, 0.04432559013366699, 0.03985849767923355, 0.018947988748550415, 0.14953306317329407, 0.0037237629294395447, -0.08868100494146347, 0.10889701545238495, 0.1895599216222763, -0.09362000226974487, -0.07342616468667984, -0.03560160845518112, 0.07950328290462494, -0.187076136469841, -0.03813624382019043, 0.05897492542862892, 0.03200775757431984, 0.016123421490192413, 0.017296720296144485, -0.0794314444065094, 0.027309413999319077, -0.1603108048439026, 0.13786724209785461, -0.1435079574584961, -0.09273369610309601, 0.014800643548369408, -0.1360984444618225, -0.10858438909053802, 0.07574291527271271, 0.04744153842329979, -0.1393163502216339, -0.055744871497154236, 0.05247379094362259, 0.04814598709344864, 0.20780418813228607, 0.04209499806165695, -0.06806778162717819, -0.07171213626861572, 0.10324528068304062, 0.05470172315835953, -0.09799909591674805, -0.07544977217912674, 0.07342208176851273, 0.021204940974712372, 0.05665721744298935, -0.047481365501880646, -0.13850775361061096, -0.0028373636305332184, -0.0007122366223484278, 0.06449979543685913, 0.05744727700948715, -0.007010696455836296, -0.08176830410957336, 0.00390893779695034, 0.09041240811347961, 0.11757579445838928, -0.04326782003045082, 0.04358863830566406, 0.0728585422039032, -0.04150572791695595, 0.035429876297712326, 0.20698955655097961, 0.14260897040367126, 0.06772108376026154, -0.06251455098390579, -0.016416063532233238, 0.06786005944013596, 0.11587817966938019, -0.07489779591560364, 0.03951927274465561, -0.04599156230688095, -0.037477947771549225, 0.05146227777004242, 0.0933970957994461, 0.06692379713058472, 0.25451526045799255, 0.09200026839971542, -0.06399991363286972, 0.058941975235939026, 0.03925306349992752, -0.08296613395214081, -0.07354166358709335, 0.057240478694438934, -0.09911379218101501, 0.031452447175979614, 0.007458887994289398, -0.019773589447140694, -0.1906743347644806, -0.04138495400547981, -0.014391202479600906, -0.09012210369110107, 0.06776949018239975, -0.15602819621562958, -0.07455503940582275, 0.1068008691072464, 0.0028655510395765305, -0.12828612327575684, 0.07838788628578186, 0.003398522501811385, -0.037809818983078, 0.11190107464790344, 0.018025491386651993, 0.0002080479171127081, 0.10628220438957214, -0.18334650993347168, -0.016429882496595383, 0.024370823055505753, 0.15188530087471008, -0.05183115601539612, 0.10530304163694382, 0.09547421336174011, 0.028433118015527725, 1.5265766037200908e-32, 0.04273679107427597, -0.07689248770475388, 0.09869442880153656, 0.06826472282409668, 0.0846853107213974, 0.03834771737456322, 0.040429189801216125, -0.02146061696112156, -0.14454011619091034, -0.11290928721427917, -0.0583936870098114, -0.0037422310560941696, 0.02255321480333805, 0.08379855751991272, 0.04039842635393143, -0.09332605451345444, 0.0695689395070076, 0.030572421848773956, -0.017510805279016495, -0.06283445656299591, 0.021314039826393127, -0.0012953663244843483, -0.08008211106061935, 0.04026736319065094, -0.1786220371723175, 0.06767582148313522, 0.010474201291799545, 0.16603168845176697, -0.07430978119373322, 0.03544437512755394, -0.22320471704006195, -0.10328635573387146, 0.04855947941541672, -0.042863018810749054, -0.1948283612728119, -0.11067529767751694, -0.001506824977695942, -0.11660066246986389, 0.09917682409286499, 0.017705345526337624, -0.04518110677599907, 0.01592824049293995, 0.0504315048456192, -0.06991013884544373, 0.019256269559264183, -0.1479436159133911, -0.08608612418174744, -0.003556925803422928, -0.06727755069732666, 0.026027366518974304, -0.014069484546780586, -0.15237371623516083, -0.001369287259876728, 0.028020694851875305, -0.12730078399181366, 0.06039363890886307, -0.20477473735809326, 0.042603831738233566, 0.1240118145942688, 0.04103962704539299, 0.048600949347019196, -0.006523309275507927, 0.1889212727546692, 0.026713240891695023, 0.061303138732910156, 0.11156973987817764, -0.03844127058982849, -0.1974709928035736, -0.09120039641857147, 0.06810025870800018, -0.0381421335041523, -0.023516695946455002, 0.21711352467536926, 0.030350180342793465, 0.11691422760486603, 0.032746821641922, 0.10514670610427856, 0.18089540302753448, 0.014998784288764, 0.11009028553962708, -0.18482846021652222, -0.028931010514497757, -0.10556076467037201, 0.20370659232139587, -0.027867155149579048, -0.12099246680736542, -0.02656213939189911, -0.02645535208284855, -0.05381475016474724, 0.05816818028688431, 0.14652875065803528, -0.011053125374019146, -0.052714794874191284, 0.07370084524154663, 0.0892554223537445, -1.432096539146337e-32, 0.00041850004345178604, 0.028399350121617317, 0.06245129182934761, -0.09586748480796814, -0.09869732707738876, 0.1325656771659851, 0.123394675552845, -0.16748258471488953, 0.1133052408695221, -0.21207766234874725, 0.03672460839152336, 0.01831994578242302, -0.057299043983221054, -0.1279958188533783, -0.12480553984642029, 0.056966520845890045, -0.017536841332912445, 0.025272062048316002, -0.11093851923942566, -0.026072796434164047, 0.05945920571684837, 0.1572912186384201, -0.02325737662613392, -0.0077561186626553535, -0.1312004178762436, -0.0283399298787117, 0.18042533099651337, 0.007874568924307823, 0.02119738794863224, -0.020295528694987297, -0.02801218070089817, 0.09630534052848816, -0.20682968199253082, 0.009175067767500877, -0.04973766952753067, -0.0571025125682354, 0.03073384240269661, -0.152407705783844, -0.07070111483335495, -0.0854349210858345, 0.0547778382897377, 0.22788101434707642, -0.10712024569511414, -0.11729578673839569, -0.004141935147345066, -0.0299203060567379, 0.10222291946411133, 0.02033025398850441, 0.17093965411186218, -0.15917500853538513, -0.061961837112903595, 0.020547963678836823, 0.02402045577764511, 0.036080118268728256, 0.012576751410961151, -0.07342328131198883, 0.06969955563545227, -0.012158537283539772, -0.006658725440502167, 0.05878423526883125, -0.048307519406080246, 0.07032627612352371, 0.009620467200875282, -0.039194680750370026, 0.05123305320739746, 0.21916118264198303, 0.030428141355514526, -0.02097594365477562, 0.1365451067686081, -0.09325974434614182, 0.02877884916961193, -0.01315575372427702, 0.009886082261800766, 0.06894704699516296, -0.02047755941748619, 0.1405533105134964, 0.11092714965343475, -0.13852782547473907, -0.05717809125781059, -0.046277277171611786, -0.09864026308059692, -0.06434385478496552, -0.10199552774429321, -0.011128397658467293, -0.1078215166926384, 0.0221218541264534, 0.03626401722431183, -0.008324596099555492, 0.003755412995815277, 0.021979402750730515, -0.05620252341032028, -0.06337812542915344, -0.07350890338420868, 0.16842040419578552, -0.028614642098546028, -1.0072525924442743e-07, 0.0813019722700119, -0.08366391807794571, 0.01845833659172058, -0.14710599184036255, -0.021266091614961624, 0.08168166875839233, -0.05287027359008789, -0.06447197496891022, -0.07363837957382202, 0.04864661768078804, 0.045455098152160645, 0.17426757514476776, -0.09413383901119232, -0.08303046226501465, -0.04134683310985565, 0.007106390781700611, 0.15665027499198914, 0.04142962396144867, -0.08828774094581604, -0.021221769973635674, -0.07355004549026489, -0.05649373680353165, -0.10791553556919098, -0.12670186161994934, 0.07493395358324051, 0.056073907762765884, 0.03693488985300064, 0.16177338361740112, 0.0971328467130661, -0.09531883150339127, 0.03529786318540573, -0.12206143140792847, 0.032897524535655975, 0.08058679103851318, 0.09719301760196686, 0.06019848585128784, -0.09995625913143158, 0.018496060743927956, 0.04280885308980942, 0.22638651728630066, -0.04883034527301788, -0.13831648230552673, 0.051544900983572006, 0.0013869982212781906, -0.12338715046644211, 0.05452578514814377, -0.10958926379680634, -0.07046984136104584, -0.008969665504992008, -0.038320478051900864, 0.07626908272504807, 0.028227919712662697, 0.00790492445230484, -0.1075981855392456, -0.09878727793693542, 0.09187465906143188, -0.1045093834400177, -0.10644084215164185, 0.12128225713968277, -0.07610583305358887, 0.12213572859764099, -0.16133368015289307, 0.0033091362565755844, 0.014659492298960686], "changes": {"1wk": -22.326147771659887, "1mo": -19.398131062075937}}, {"text": "LIVE The latest news and updates on Trump's tariffs Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 San Antonio Breast Cancer Symposium Arvinas Inc. Tue, Nov 26, 2024, 1:35 AM 5 min read In This Article: ARVN Arvinas Inc. NEW HAVEN, Conn., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that three posters for vepdegestrant, including clinical data, will be presented at the 2024 San Antonio Breast Cancer Symposium (SABCS), being held December 10-13, 2024, in San Antonio, Texas. Vepdegestrant is a novel investigational PROTAC estrogen receptor (ER) degrader that is being jointly developed by Arvinas and Pfizer for the treatment of patients with early and locally advanced or metastatic estrogen receptor positive/human epidermal growth factor receptor 2 (HER2) negative (ER+/HER2-) breast cancer. Poster session details are as follows: Poster Title : Evaluation of the Combination of Vepdegestrant, a PROTAC Estrogen Receptor (ER) Degrader, Plus Palbociclib in CDK4/6 Inhibitor-Resistant WT ER and ER Y537S Mutant Patient Derived Xenograft (PDX) Models Poster Session 3 (ID: P3-01-16) Date : Thursday, December 12 Time : 12:30 p.m. \u2013 2:00 p.m. CT Poster Title : Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, Plus Abemaciclib in ER-Pos/Human Epidermal Growth Factor Receptor 2 (HER2) Negative Advanced or Metastatic Breast Cancer: TACTIVE-U Prelim Phase 1b Results Poster Session 4 (ID: P4-12-03) Date : Thursday, December 12 Time : 5:30 p.m. \u2013 7:00 p.m. CT Poster Title : Evaluating CYP3A4-Mediated Drug Interaction Risks for Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, in Combination with Cyclin Dependent Kinase (CDK)4/6 Inhibitors and Everolimus Poster Session 4 (ID: P4-08-13) Date : Thursday, December 12 Time : 5:30 p.m. \u2013 7:00 p.m. CT For copies of the abstracts, please visit the official SABCS website here . About Vepdegestrant Vepdegestrant is an investigational, orally bioavailable PROTAC protein degrader designed to specifically target and degrade the estrogen receptor (ER) for the treatment of patients with ER positive (ER+)/human epidermal growth factor receptor 2 (HER2) negative (ER+/HER2-) breast cancer. Vepdegestrant is being developed as a potential monotherapy and as part of combination therapy across multiple treatment settings for ER+/HER2- metastatic breast cancer. In July 2021, Arvinas announced a global collaboration with Pfizer for the co-development and co-commercialization of vepdegestrant; Arvinas and Pfizer will share worldwide development costs, commercialization expenses, and profits. The U.S. Food and Drug Administration (FDA) has granted vepdegestrant Fast Track designation as a monotherapy in the treatment of adults with ER+/HER2- locally advanced or metastatic breast cancer previously treated with endocrine-based therapy. Story Continues About\u00a0Arvinas Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC\u00a0(PROteolysis TArgeting Chimera) protein degrader platform, the Company is pioneering the development of protein degradation therapies designed to harness the body\u2019s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; and ARV-102, targeting LRRK2 for neurodegenerative disorders. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit www.arvinas.com and connect on LinkedIn and X . Forward-Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding the potential of vepdegestrant as a monotherapy and as part of combination therapy to potentially treat patients with ER+/HER2- metastatic breast cancer. Statements regarding Arvinas\u2019 strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words \u201canticipate,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cplan,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201ctarget,\u201d \u201cgoal,\u201d \u201cpotential,\u201d \u201cwill,\u201d \u201cwould,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201ccontinue,\u201d and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Arvinas may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on such forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements Arvinas makes as a result of various risks and uncertainties, including but not limited to: Arvinas\u2019 and Pfizer\u2019s performance of the respective obligations with respect to Arvinas\u2019 collaboration with Pfizer; whether Arvinas and Pfizer will be able to successfully conduct and complete clinical development for vepdegestrant; whether Arvinas and Pfizer, as appropriate, will be able to obtain marketing approval for and commercialize vepdegestrant on current timelines or at all; Arvinas\u2019 ability to protect its intellectual property portfolio; whether Arvinas\u2019 cash and cash equivalent resources will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements, and other important factors discussed in the \u201cRisk Factors\u201d section of Arvinas\u2019 Annual Report on Form 10-K for the year ended December 31, 2023 and subsequent other reports on file with the U.S. Securities and Exchange Commission. The forward-looking statements contained in this press release reflect Arvinas\u2019 current views with respect to future events, and Arvinas assumes no obligation to update any forward-looking statements, except as required by applicable law. These forward-looking statements should not be relied upon as representing Arvinas\u2019 views as of any date subsequent to the date of this release. Contacts Investors: Jeff Boyle +1 (347) 247-5089 Jeff.Boyle@arvinas.com Media: Kirsten Owens +1 (203) 584-0307 Kirsten.Owens@arvinas.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "ARVN", "date": "2024-11-26T01:35:00", "sentiment": {"score": 0.028067413717508316, "confidence": 0.04809338599443436, "probabilities": {"positive": 0.04809338599443436, "negative": 0.02002597227692604, "neutral": 0.9318806529045105}}, "embedding": [-0.029897799715399742, -0.21845486760139465, -0.11319002509117126, -0.10534073412418365, 0.13480153679847717, -0.02646866999566555, -0.09250508248806, 0.19151481986045837, 0.06460843235254288, 0.144001305103302, 0.046406783163547516, 0.05565205588936806, -0.04574308171868324, 0.08219566941261292, 0.012636302970349789, 0.23458117246627808, -0.04261019825935364, 0.020609527826309204, 0.10340617597103119, 0.15892767906188965, 0.03514150530099869, -0.08671325445175171, 0.048280857503414154, 0.1328601837158203, -0.10930755734443665, -0.012527897022664547, -0.03923387825489044, 0.10798680037260056, -0.2593102753162384, -0.11478467285633087, -0.018565278500318527, 0.0010289065539836884, -0.021777629852294922, 0.015785716474056244, -0.01820254512131214, 0.009738284163177013, -0.10908735543489456, 0.06493796408176422, -0.03640851750969887, -0.06516389548778534, 0.027774924412369728, -0.11230400204658508, -0.1962275207042694, 0.024895867332816124, 0.09027942270040512, -0.11955037713050842, -0.0435202531516552, 0.05721072107553482, 0.02358006313443184, 0.12661460041999817, 0.06211822107434273, -0.03747782111167908, -0.05156484246253967, 0.08366604149341583, -0.05875442922115326, -0.015703938901424408, -0.10820715129375458, -0.010150579735636711, 0.013862098567187786, 0.07658588886260986, -0.00023976527154445648, -0.12048205733299255, 0.006852569058537483, -0.03513392433524132, 0.037427276372909546, 0.08279592543840408, -0.04077698290348053, 0.0026245340704917908, 0.010023653507232666, 0.051239319145679474, -0.013688329607248306, -0.0026954403147101402, -0.027539148926734924, 0.11483335494995117, 0.022426065057516098, 0.058586396276950836, 0.23632854223251343, 0.11487692594528198, 0.08975788205862045, -0.14791655540466309, -0.002447516890242696, 0.06831212341785431, 0.08886021375656128, -0.008906587958335876, -0.032301947474479675, -0.015597272664308548, -0.0780770555138588, -0.020547516644001007, 0.10377339273691177, 0.07999417185783386, 0.2254599928855896, 0.08159017562866211, -0.09876112639904022, 0.06359711289405823, 0.07294264435768127, 0.05886244401335716, -0.13076171278953552, 0.02718058042228222, 0.024717114865779877, 0.01146912295371294, 0.01629689522087574, 0.04594941437244415, -0.16845297813415527, -0.1058003157377243, -0.02261260710656643, -0.0728442519903183, 0.08095922321081161, -0.08984105288982391, -0.04074816405773163, 0.0494147352874279, -0.056143686175346375, -0.15315070748329163, 0.03600116819143295, 0.015570570714771748, -0.04463733360171318, 0.2027515470981598, -0.0036206827498972416, -0.017012670636177063, 0.09435828775167465, -0.19379183650016785, -0.022717859596014023, 0.06571250408887863, 0.07719841599464417, 0.08346491307020187, 0.12247928977012634, 0.10858699679374695, -0.11384620517492294, 1.4201145782916117e-32, 0.04221584275364876, -0.06341594457626343, 0.06202346831560135, 0.04937824234366417, 0.061557672917842865, 0.12326496839523315, 0.03882475942373276, -0.037923116236925125, -0.1337922066450119, -0.16220244765281677, -0.12901850044727325, -0.029474381357431412, -0.03053385391831398, -0.009077578783035278, 0.028252867981791496, -0.06090573966503143, 0.04675353318452835, 0.13845734298229218, 0.005744571331888437, -0.10619477927684784, -0.008393646217882633, 0.03809938579797745, -0.039669930934906006, -0.019384726881980896, -0.08195631206035614, 0.22810891270637512, -0.00041319243609905243, 0.1312115490436554, -0.030998634174466133, -0.006224667653441429, -0.2538444995880127, -0.048376649618148804, 0.09935124218463898, -0.0017538201063871384, -0.07786133885383606, -0.13089632987976074, -0.041186921298503876, -0.14177227020263672, 0.08605970442295074, 0.031119458377361298, 0.01676970347762108, 0.04732123017311096, 0.05607232823967934, -0.008177876472473145, 0.051316916942596436, -0.20544707775115967, 0.04090644791722298, 0.1152029037475586, 0.018176790326833725, -0.015608927235007286, -0.038149867206811905, -0.1214241310954094, 0.03125279024243355, 0.00013752561062574387, -0.12232571095228195, 0.018880851566791534, -0.19520051777362823, -0.004046275280416012, 0.16548579931259155, 0.004585777409374714, -0.00902506336569786, 0.03334223851561546, 0.10244511067867279, 0.0010433325078338385, 0.1139836460351944, 0.08160834014415741, -0.11746981739997864, -0.09312430769205093, -0.07936353981494904, 0.10105982422828674, -0.0072931330651044846, -0.0544685423374176, 0.35423168540000916, 0.061673812568187714, 0.17671024799346924, 0.018788542598485947, 0.021068057045340538, 0.21748360991477966, 0.015715187415480614, 0.031512703746557236, -0.21991446614265442, 0.058372948318719864, -0.14950114488601685, 0.2063715159893036, -0.004917088896036148, -0.14310765266418457, 0.03773443400859833, -0.08042403310537338, 0.007132459431886673, 0.051088519394397736, 0.11019815504550934, -0.052304692566394806, -0.09262494742870331, 0.1352369338274002, 0.05306033417582512, -1.2822790494500673e-32, -0.033303484320640564, 0.0448894277215004, -0.021197598427534103, -0.06501877307891846, -0.04231278598308563, 0.03819584473967552, 0.0639813020825386, -0.10471156239509583, 0.11841006577014923, -0.176273912191391, 0.03021187148988247, -0.05202146992087364, -0.0060022734105587006, -0.15084993839263916, -0.07541777938604355, 0.10903066396713257, -0.030130082741379738, -0.0423128679394722, -0.1903507262468338, -0.058568745851516724, -0.05211351439356804, 0.1641799509525299, -0.04389581456780434, 0.028237275779247284, 0.024367421865463257, 0.026827849447727203, 0.2627728581428528, 0.06030590832233429, 0.003550637513399124, -0.043709807097911835, -0.06243276596069336, 0.09255179762840271, -0.2502487599849701, 0.034508299082517624, -0.025606941431760788, -0.019214006140828133, -0.022499043494462967, -0.11652123928070068, -0.005121137015521526, -0.13252978026866913, 0.07956495136022568, 0.14728987216949463, -0.10368211567401886, -0.08439068496227264, 0.01144714467227459, 0.09213277697563171, 0.14235106110572815, 0.06540511548519135, 0.1103179007768631, -0.05956096202135086, -0.06821220368146896, -0.058313652873039246, -0.010370355099439621, 0.005572852212935686, 0.020202120766043663, -0.010681351646780968, 0.05133780837059021, 0.00505675096064806, -0.012117135338485241, 0.04447086155414581, -0.0807558223605156, 0.03157142177224159, 0.09271908551454544, -0.06202545762062073, 0.039175260812044144, 0.15233385562896729, 0.038674525916576385, 0.02339266613125801, 0.08719224482774734, 0.011025134474039078, 0.011268763802945614, -0.0135032394900918, -0.08456740528345108, 0.03775753825902939, 0.02228529378771782, 0.1362665295600891, -0.03978767618536949, -0.1533721685409546, -0.0560091957449913, -0.03248972445726395, -0.11259466409683228, -0.0839196965098381, -0.10780337452888489, -0.08550006151199341, 0.02057424746453762, 0.05415516346693039, -0.05796151980757713, 0.23992691934108734, -0.019700873643159866, 0.0907970666885376, -0.023489180952310562, -0.09094318747520447, -0.07664629817008972, 0.1994238644838333, -0.049360666424036026, -9.990233706957952e-08, 0.04351818934082985, -0.026839235797524452, 0.11238144338130951, -0.19285982847213745, 0.00713326595723629, -0.011021691374480724, 0.03445456549525261, 0.009197108447551727, -0.054251156747341156, -0.007041743025183678, 0.0723293274641037, 0.13018563389778137, -7.169877062551677e-05, -0.185770645737648, -0.012376224622130394, 0.03538031503558159, 0.1425950527191162, 0.058584652841091156, -0.1540708690881729, -0.10880632698535919, -0.032392095774412155, -0.08649750798940659, -0.15003296732902527, -0.11905202269554138, 0.09681699424982071, -0.05005528777837753, -0.02726827561855316, 0.15100125968456268, 0.0044694035314023495, -0.116621233522892, 0.11798875033855438, -0.04589076340198517, 0.026659373193979263, -0.011095831170678139, 0.13937726616859436, 0.039261870086193085, 0.019512854516506195, -0.017659269273281097, 0.030523091554641724, 0.17636454105377197, -0.0612851083278656, -0.12824735045433044, -0.03722882643342018, -0.015862099826335907, -0.12162548303604126, 0.002924105152487755, -0.030261453241109848, -0.08767089247703552, 0.06013111397624016, -0.014126833528280258, -0.05169659107923508, -0.048892468214035034, -0.004818722605705261, -0.12816274166107178, -0.04343058168888092, 0.09836061298847198, -0.0651160329580307, -0.0690976232290268, 0.08974675834178925, -0.02450420893728733, 0.0914749875664711, -0.14377519488334656, 0.08643463253974915, 0.10260341316461563], "changes": {"1wk": 2.266400411410935, "1mo": -25.526839656743977}}, {"text": "LIVE The latest news and updates on Trump's tariffs Arvinas and Pfizer Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium Arvinas Inc. Tue, Dec 10, 2024, 5:05 PM 11 min read In This Article: PFE ARVN Arvinas Inc. \u2013 Vepdegestrant in combination with abemaciclib demonstrated encouraging clinical activity (clinical benefit rate: 62.5%; overall response rate: 26.7%) in patients previously treated with a CDK4/6 inhibitor \u2013 \u2013 Safety and tolerability of the combination is generally consistent with the profile of abemaciclib and what has been observed in other clinical trials of vepdegestrant; no significant drug-drug interaction was observed between vepdegestrant and abemaciclib \u2013 \u2013 Recommended Phase 2 dose identified as 200 mg QD vepdegestrant and 150 mg BID abemaciclib \u2013 NEW HAVEN, Conn. and NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced preliminary data from the ongoing Phase 1b portion of the TACTIVE-U sub-study of vepdegestrant in combination with abemaciclib among patients with locally advanced or metastatic estrogen receptor positive (ER+)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer. These data will be presented in a poster at the 2024 San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas. Preliminary results from 16 patients in the Phase 1b sub-study demonstrated a tolerable safety profile for the combination of abemaciclib 150 mg twice daily (BID) with the recommended Phase 3 monotherapy dose of vepdegestrant (200mg once daily; QD). An encouraging clinical benefit rate of 62.5% was observed among patients with both mutant ESR1 and wild-type ESR1 disease who had all been previously treated with a CDK4/6 inhibitor. Pharmacokinetic data demonstrated no significant drug-drug interaction between vepdegestrant and abemaciclib and no clinically meaningful effect on abemaciclib exposure was observed. In addition to tolerability, the results demonstrated a safety profile consistent with both the known properties of abemaciclib and observed data in other clinical trials for vepdegestrant. These findings support the ongoing Phase 2 portion of the study, which is evaluating full dose abemaciclib (150mg BID) in combination with vepdegestrant (200 mg QD) in post-CDK4/6 advanced breast cancer. \u201cThe preliminary results from this Phase 1b sub-study in patients whose cancer had previously progressed after receiving a CDK4/6 inhibitor are encouraging,\u201d said Noah Berkowitz, M.D., Ph.D., Chief Medical Officer at Arvinas. \u201cThese data further reinforce our belief that vepdegestrant can be used in multiple combination regimens across the metastatic breast cancer setting and has the potential to become a best-in-class backbone ER therapy. We are pleased to continue in the Phase 2 portion of the study evaluating the standard starting dose of abemaciclib in combination with vepdegestrant.\u201d Story Continues \u201cWith vepdegestrant, we aim to develop a novel agent that has the potential to become a new backbone endocrine therapy in ER+ metastatic breast cancer,\u201d said Roger Dansey, M.D., Chief Development Officer, Oncology, Pfizer\u200b. \u201cWe are pleased to see these initial results, which complement previously reported data demonstrating the potential of combination therapy with vepdegestrant to address unmet needs for patients.\u201d Additional detail on the TACTIVE-U poster presentation at SABCS follows below: Title: Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, Plus Abemaciclib in ER-Positive/Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced or Metastatic Breast Cancer: TACTIVE-U Preliminary Phase 1b Results Date: Thursday, December 12, 2024 Time: 5:30 - 7:00 p.m. CDT Poster: P4-12-03 Key findings included in the poster (data cut-off: August 30, 2024): 100% of patients had prior treatment with a CDK4/6 inhibitor. Tolerability is generally consistent with the profile of abemaciclib and with results previously observed in other clinical trials of vepdegestrant. The most common any grade treatment-emergent adverse events (TEAE) were diarrhea, nausea and fatigue. There were no dose-limiting toxicities and no grade 4 or 5 TEAEs. There was no significant drug-drug interaction, and data reflected vepdegestrant has no clinically meaningful effect on abemaciclib exposure. Encouraging preliminary antitumor activity is observed with a clinical benefit rate (CBR, defined as the rate of confirmed complete response, partial response, or stable disease \u2265 24 weeks) of 62.5% in all CBR-eligible patients (10/16), 62.5% in patients with mutant ESR1 (5/8), and 62.5% in patients with wild-type ESR1 (5/8). The objective response rate (ORR) in evaluable patients was 26.7% overall (4/15), 37.5% in patients with mutant ESR1 (3/8), and 14% in patients with wild-type ESR1 (1/7). Five patients remained on study treatment as of the August 30, 2024 data cut-off. Arvinas and Pfizer are continuing to evaluate data from the ongoing TACTIVE-U clinical trial, which includes combinations of vepdegestrant plus abemaciclib, ribociclib or samuraciclib (ClinicalTrials.gov Identifiers: NCT05548127, NCT05573555, and NCT06125522). About Vepdegestrant Vepdegestrant is an investigational, orally bioavailable PROTAC protein degrader designed to specifically target and degrade the estrogen receptor (ER) for the treatment of patients with ER positive (ER+)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer. Vepdegestrant is being developed as a potential monotherapy and as part of combination therapy across multiple treatment settings for ER+/HER2- metastatic breast cancer. In July 2021, Arvinas announced a global collaboration with Pfizer for the co-development and co-commercialization of vepdegestrant; Arvinas and Pfizer will share worldwide development costs, commercialization expenses, and profits. The U.S. Food and Drug Administration (FDA) has granted vepdegestrant Fast Track designation as a monotherapy in the treatment of adults with ER+/HER2- locally advanced or metastatic breast cancer previously treated with endocrine-based therapy. About\u00a0Arvinas Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC\u00a0(PROteolysis TArgeting Chimera) protein degrader platform, the Company is pioneering the development of protein degradation therapies designed to harness the body\u2019s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; and ARV-102, targeting LRRK2 for neurodegenerative disorders. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit www.arvinas.com and connect on LinkedIn and X . Arvinas Forward-Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding whether vepdegestrant can be used in multiple combination regimens across the metastatic breast cancer setting; whether the potential to become a best-in-class backbone estrogen receptor therapy; Arvinas and Pfizer\u2019s plans with respect to the Phase 2 portion of the TACTIVE-U clinical trial evaluating the standard starting dose of abemaciclib in combination with vepdegestrant; the potential, pending regulatory approval, for vepdegestrant to address an area of high unmet need; Arvinas\u2019 and Pfizer\u2019s plans with respect to, the timing and results of ongoing and planned clinical trials of vepdegestrant, as a monotherapy and in combination studies; and statements regarding potential therapeutic benefits of vepdegestrant. All statements, other than statements of historical facts, contained in this press release, including statements regarding Arvinas\u2019 strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words \u201canticipate,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cplan,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201ctarget,\u201d \u201cpotential,\u201d \u201cwill,\u201d \u201cwould,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201ccontinue,\u201d and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Arvinas may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on such forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements Arvinas makes as a result of various risks and uncertainties, including but not limited to: Arvinas\u2019 and Pfizer Inc.\u2019s (\u201cPfizer\u201d) performance of the respective obligations with respect to Arvinas\u2019 collaboration with Pfizer; whether Arvinas and Pfizer will be able to successfully conduct and complete clinical development for vepdegestrant; whether Arvinas and Pfizer, as appropriate, will be able to obtain marketing approval for and commercialize vepdegestrant on current timelines or at all; Arvinas\u2019 ability to protect its intellectual property portfolio; whether Arvinas\u2019 cash and cash equivalent resources will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements; and other important factors discussed in the \u201cRisk Factors\u201d section of Arvinas\u2019 Annual Report on Form 10-K for the year ended December 31, 2023, and subsequent other reports on file with the U.S. Securities and Exchange Commission. The forward-looking statements contained in this press release reflect Arvinas\u2019 current views with respect to future events, and Arvinas assumes no obligation to update any forward-looking statements, except as required by applicable law. These forward-looking statements should not be relied upon as representing Arvinas\u2019 views as of any date subsequent to the date of this release. About Pfizer Oncology At Pfizer Oncology, we are at the forefront of a new era in cancer care. Our industry-leading portfolio and extensive pipeline includes three core mechanisms of action to attack cancer from multiple angles, including small molecules, antibody-drug conjugates (ADCs), and bispecific antibodies, including other immune-oncology biologics. We are focused on delivering transformative therapies in some of the world\u2019s most common cancers, including breast cancer, genitourinary cancer, hematology-oncology, and thoracic cancers, which includes lung cancer. Driven by science, we are committed to accelerating breakthroughs to help people with cancer live better and longer lives. About Pfizer: Breakthroughs That Change Patients\u2019 Lives At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development, and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments, and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world\u2019s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments, and local communities to support and expand access to reliable, affordable health care around the world. For 175 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com . In addition, to learn more, please visit us on www.Pfizer.com and follow us on X at @Pfizer and @Pfizer News , LinkedIn , YouTube and like us on Facebook at Facebook.com/Pfizer . Pfizer Disclosure Notice The information contained in this release is as of December 10, 2024. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments. This release contains forward-looking information about preliminary data from the ongoing Phase 1B portion of the TACTIVE-U sub-study of vepdegestrant in combination with abemaciclib, among patients with locally advanced or metastatic estrogen receptor (ER) positive/human epidermal growth factor 2 (HER2) negative (ER+/HER2-) breast cancer, including their potential benefits, as well as the ongoing Phase 2 portion of the study, that involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when drug applications may be filed in any jurisdictions for any potential indication for vepdegestrant in combination with abemaciclib; whether and when any such applications that may be filed for vepdegestrant in combination with abemaciclib or any other such product candidates may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product's benefits outweigh its known risks and determination of the product's efficacy and, if approved, whether vepdegestrant in combination with abemaciclib or any such other product candidates will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of vepdegestrant in combination with abemaciclib or any such other product candidates; uncertainties regarding the impact of COVID-19 on our business, operations and financial results; and competitive developments. A further description of risks and uncertainties can be found in Pfizer\u2019s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and in its subsequent reports on Form 10-Q, including in the sections thereof captioned \u201cRisk Factors\u201d and \u201cForward-Looking Information and Factors That May Affect Future Results\u201d, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com . Arvinas Contacts: Investor Contact: Jeff Boyle, Arvinas Investor Relations 347-247-5089 Jeff.Boyle@arvinas.com Media Contact: Kirsten Owens, Arvinas Communications 203-584-0307 Kirsten.Owens@arvinas.com Pfizer Contacts: Investor Contact: +1 (212) 733-4848 IR@Pfizer.com Media Contact: +1 (212) 733-1226 PfizerMediaRelations@Pfizer.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "ARVN", "date": "2024-12-10T17:05:00", "sentiment": {"score": 0.15003165788948536, "confidence": 0.1673204004764557, "probabilities": {"positive": 0.1673204004764557, "negative": 0.01728874258697033, "neutral": 0.8153908252716064}}, "embedding": [0.05503999441862106, -0.14282441139221191, -0.0713372603058815, -0.08846868574619293, 0.11522513628005981, -0.14090603590011597, -0.08635909855365753, 0.21895766258239746, 0.039882391691207886, 0.04479485750198364, -0.0992199033498764, 0.026360053569078445, 0.07220607250928879, 0.008255773223936558, 0.022126244381070137, 0.20895561575889587, 0.053887538611888885, 0.06512067466974258, -0.008703779429197311, 0.12369482964277267, 0.05957971513271332, -0.07717303931713104, 0.12536859512329102, 0.17070063948631287, -0.11797821521759033, -0.05039647966623306, -0.01680641621351242, 0.0802762508392334, -0.24252498149871826, -0.03977908939123154, 0.055058956146240234, -0.016800617799162865, 0.03351272642612457, 0.07164108753204346, -0.016036532819271088, 0.012712625786662102, -0.10974518209695816, 0.17033156752586365, -0.14568296074867249, -0.1224387139081955, -0.011548741720616817, -0.0872211679816246, -0.08897542953491211, 0.0810089185833931, 0.061727579683065414, -0.12130257487297058, -0.07506381720304489, 0.0520629845559597, 0.05907842516899109, 0.19244417548179626, 0.08473695069551468, -0.07163105905056, -0.05096396058797836, 0.09416980296373367, 0.04923413693904877, -0.060720816254615784, -0.10825130343437195, 0.046227358281612396, 0.03515513613820076, 0.1060781180858612, -0.017918601632118225, -0.13912047445774078, 0.017952103167772293, -0.011853051371872425, 0.08150134980678558, 0.08941170573234558, 0.017840426415205002, -0.06896133720874786, 0.016391431912779808, 0.07184122502803802, 0.09766754508018494, -0.07652898132801056, 0.058465223759412766, 0.05340989679098129, -0.00841255858540535, 0.04199729487299919, 0.21267876029014587, 0.13130731880664825, 0.09082422405481339, -0.08692312240600586, -0.037998151034116745, 0.047514740377664566, 0.1186995580792427, -0.10342132300138474, -0.011303113773465157, -0.04285877197980881, -0.05974026024341583, 0.020525477826595306, 0.07688920199871063, 0.06858649104833603, 0.2796260714530945, 0.05002244561910629, -0.05986471474170685, 0.08496604859828949, 0.08769406378269196, -0.07258962094783783, -0.0591929592192173, 0.046538908034563065, -0.04601084440946579, -0.008845565840601921, -0.008087461814284325, -0.05292189493775368, -0.17120711505413055, -0.03954896330833435, 0.04983058199286461, -0.15769098699092865, 0.11986862123012543, -0.16171681880950928, -0.038850463926792145, 0.08197769522666931, 0.020065300166606903, -0.12045319378376007, 0.11578327417373657, 0.00590480538085103, -0.0017277183942496777, 0.17681476473808289, 0.033227503299713135, 0.004578335676342249, 0.11376437544822693, -0.1884198635816574, 0.014929313212633133, 0.051999904215335846, 0.1347954422235489, -0.02827022410929203, 0.12258347868919373, 0.06917659938335419, -0.00921070296317339, 1.3230171286089584e-32, 0.019506778568029404, -0.08210942149162292, 0.1185595691204071, 0.06427505612373352, 0.04496275633573532, 0.018632180988788605, 0.01551566831767559, 0.0064206598326563835, -0.14798203110694885, -0.09267126023769379, -0.0887804850935936, -0.03524626046419144, 0.03471120819449425, 0.13553747534751892, 0.061465926468372345, -0.08734074234962463, 0.10227254033088684, 0.003425830975174904, 0.03758053854107857, -0.06443855166435242, -0.00645733717828989, -0.00375544186681509, -0.05726035311818123, 0.0538167729973793, -0.17069359123706818, 0.12412950396537781, 0.0003349697217345238, 0.15239956974983215, -0.006555202417075634, 0.04230669513344765, -0.24307291209697723, -0.0581698939204216, 0.05399923771619797, -0.026334762573242188, -0.15334324538707733, -0.11290182173252106, -0.015983084216713905, -0.03214403986930847, 0.08622593432664871, -0.03281762823462486, -0.050009213387966156, 0.009743454866111279, -0.020837057381868362, -0.04824040085077286, 0.07504361867904663, -0.15200889110565186, -0.04761318862438202, 0.020862707868218422, -0.05488329008221626, -0.02707476168870926, 0.012831676751375198, -0.14081710577011108, 0.020272813737392426, 0.004601486027240753, -0.1136154904961586, 0.04725810885429382, -0.17508679628372192, 0.01479372102767229, 0.15250588953495026, 0.06133003532886505, 0.05013808608055115, 0.028538359329104424, 0.16054067015647888, 0.03354637697339058, 0.0762755274772644, 0.1247791051864624, -0.062309108674526215, -0.1420205682516098, -0.10440272092819214, 0.06145431846380234, -0.017917415127158165, 0.003800070844590664, 0.26209646463394165, 0.08158697932958603, 0.11373739689588547, 0.058524005115032196, 0.08887487649917603, 0.18697889149188995, -0.04823536053299904, 0.09495317935943604, -0.22951287031173706, -0.04867662861943245, -0.16036435961723328, 0.19360077381134033, -0.018636338412761688, -0.08545069396495819, -0.026529531925916672, -0.02849230170249939, -0.05799032002687454, 0.05930406227707863, 0.12749868631362915, -0.013010160997509956, -0.081968754529953, 0.13372711837291718, 0.10650339722633362, -1.3685308005048588e-32, 0.0076758600771427155, 0.062028806656599045, 0.013627564534544945, -0.11700670421123505, -0.06722377240657806, 0.13365164399147034, 0.1560879349708557, -0.13422442972660065, 0.11451322585344315, -0.199938103556633, 0.007643171586096287, 0.0017922688275575638, -0.06841783225536346, -0.145083487033844, -0.1208607628941536, 0.08909882605075836, -0.07473777234554291, 0.02393190935254097, -0.10992846637964249, 0.012630729004740715, 0.040244150906801224, 0.07793893665075302, -0.02755662240087986, -0.04150661826133728, -0.09002213925123215, 0.0012956205755472183, 0.1586247980594635, 0.018805816769599915, -0.0354793518781662, -0.035814907401800156, -0.024231862276792526, 0.14964458346366882, -0.19299225509166718, -0.01511973887681961, -0.11416769027709961, -0.05008573830127716, -0.019874252378940582, -0.1823398768901825, -0.0780733972787857, -0.1234285831451416, 0.04353749752044678, 0.18992739915847778, -0.12899523973464966, -0.10815612971782684, 0.00212140753865242, -0.0020472928881645203, 0.12973450124263763, 0.05147070437669754, 0.12508046627044678, -0.20250192284584045, -0.08445500582456589, 0.025447756052017212, 0.034546948969364166, 0.010362865403294563, 0.025730308145284653, -0.0475899800658226, 0.04448986053466797, -0.0017058108933269978, -0.00687833409756422, 0.09589575231075287, -0.058662235736846924, 0.03584938868880272, 0.03686266019940376, -0.05570162460207939, 0.08236004412174225, 0.1556774526834488, 0.017704235389828682, -0.054849423468112946, 0.12867321074008942, -0.03126087784767151, 0.022402428090572357, -0.039665527641773224, -0.027511967346072197, 0.04383065924048424, -0.049140263348817825, 0.14899694919586182, 0.09190068393945694, -0.1585351526737213, -0.08935030549764633, -0.01895883120596409, -0.05153380706906319, -0.033210065215826035, -0.08637865632772446, -0.003763932269066572, -0.1317264437675476, -0.02696141228079796, 0.05048070847988129, 0.02965892106294632, -0.011054227128624916, 0.04590640217065811, -0.09925641864538193, -0.07759196311235428, -0.116670623421669, 0.1563815176486969, -0.0892745852470398, -1.0026903396465059e-07, 0.0955323576927185, -0.08491954207420349, 0.07761366665363312, -0.18627631664276123, -0.02647935226559639, 0.09251964092254639, -0.07326225936412811, 0.026587270200252533, -0.08966799080371857, 0.039332665503025055, 0.04476919770240784, 0.16439738869667053, -0.10990752279758453, -0.1078478991985321, -0.08807191997766495, 0.03207127004861832, 0.15359729528427124, 0.006797227542847395, -0.07857559621334076, -0.04894639551639557, -0.07730969786643982, -0.08373954892158508, -0.06737849116325378, -0.1251072883605957, 0.07043670862913132, 0.0047809891402721405, 0.0018473723903298378, 0.1303863674402237, 0.05080176889896393, -0.1114301085472107, 0.0251910537481308, -0.12316088378429413, 0.038518939167261124, 0.03952895104885101, 0.07128942012786865, 0.02559884637594223, -0.130275160074234, -0.009896554052829742, 0.03499407321214676, 0.181481271982193, -0.01686956360936165, -0.12947037816047668, 0.03711885213851929, 0.0039208680391311646, -0.11879360675811768, 0.018628552556037903, -0.0936034694314003, -0.058751799166202545, 0.05068489536643028, -0.056025803089141846, 0.05285398289561272, -0.017724674195051193, -0.006385854445397854, -0.11675004661083221, -0.08851755410432816, 0.09548454731702805, -0.11653485149145126, -0.11727927625179291, 0.1054004430770874, -0.05723892152309418, 0.09376990050077438, -0.13834086060523987, 0.022772306576371193, 0.040789876133203506], "changes": {"1wk": -22.773486566572362, "1mo": -19.398131062075937}}, {"text": "LIVE The latest news and updates on Trump's tariffs Arvinas and Pfizer\u2019s combo therapy shows promise in breast cancer trial A clinical benefit rate of 62.5% was noted among subjects with both mutant and wild-type oestrogen receptor alpha gene disease. Credit: Andrei_R/Shutterstock. \u00b7 Clinical Trials Arena \u00b7 Andrei_R/Shutterstock. GlobalData Wed, Dec 11, 2024, 1:38 PM 2 min read In This Article: PFE ARVN Arvinas and Pfizer have shared preliminary outcomes from the Phase Ib segment of the TACTIVE-U sub-trial of vepdegestrant plus abemaciclib for treating individuals with locally advanced or metastatic, oestrogen receptor-positive (ER+)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer. The combination demonstrated a tolerable safety profile, as per the ongoing trial\u2019s preliminary data involving 16 subjects. They received 150mg of abemaciclib two times a day, alongside the recommended Phase III monotherapy vepdegestrant dose of 200mg once a day. A clinical benefit rate of 62.5% was noted among subjects with mutant and wild-type oestrogen receptor 1 (ESR1) disease, all of whom had previously been treated with a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor. No significant drug-drug interactions were observed between vepdegestrant and abemaciclib, according to the pharmacokinetic data. A clinically meaningful effect on abemaciclib exposure also was not observed. The safety profile demonstrated was consistent with the known properties of abemaciclib, and with data from other vepdegestrant trials. These outcomes support the advancement to the Phase II segment of the trial, which will evaluate the full dose of abemaciclib and vepdegestrant in post-CDK4/6 advanced breast cancer. Ongoing evaluations of the TACTIVE-U clinical trial by both companies include various combinations of vepdegestrant with abemaciclib, ribociclib, or samuraciclib. Arvinas chief medical officer Noah Berkowitz said: \u201cThe preliminary results from this Phase Ib sub-study in patients whose cancer had previously progressed after receiving a CDK4/6 inhibitor are encouraging. \u201cThese data further reinforce our belief that vepdegestrant can be used in multiple combination regimens across the metastatic breast cancer setting, and has the potential to become a best-in-class backbone ER therapy.\u201c An orally bioavailable Proteolysis Targeting Chimera (PROTAC) protein degrader, vepdegestrant is being developed for potential use as both a single agent and as part of a combination therapy for ER+/HER2- metastatic breast cancer. In October this year, Pfizer released positive topline results from the Phase III TALAPRO-2 trial of TALZENNA plus XTANDI (enzalutamide) for individuals with metastatic castration-resistant prostate cancer (mCRPC). \"Arvinas and Pfizer\u2019s combo therapy shows promise in breast cancer trial\" was originally created and published by Clinical Trials Arena , a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "ARVN", "date": "2024-12-11T13:38:25", "sentiment": {"score": 0.41721194703131914, "confidence": 0.4294714033603668, "probabilities": {"positive": 0.4294714033603668, "negative": 0.01225945632904768, "neutral": 0.5582690834999084}}, "embedding": [0.039657529443502426, -0.11148510128259659, -0.09673561155796051, -0.06242389976978302, 0.12042291462421417, -0.16883587837219238, -0.06807488948106766, 0.20085853338241577, 0.02824646420776844, 0.00013459473848342896, -0.08042971789836884, 0.07573133707046509, 0.008614018559455872, 0.0010568811558187008, 0.009890859946608543, 0.2006104588508606, 0.012590739876031876, 0.0793246254324913, 0.042345281690359116, 0.1580287218093872, -0.02257721498608589, -0.097629614174366, 0.16589680314064026, 0.18793492019176483, -0.1433931291103363, -0.05692734196782112, -0.02134145237505436, 0.14677929878234863, -0.1572476029396057, -0.06094712018966675, 0.05647596716880798, -0.014094710350036621, 0.06659233570098877, 0.04413854330778122, -0.05807735025882721, 0.011906198225915432, -0.12242782115936279, 0.08546024560928345, -0.17909544706344604, -0.06631599366664886, 0.02159043215215206, -0.12196515500545502, -0.07545314729213715, 0.13612182438373566, 0.0768052488565445, -0.07363001257181168, -0.027625039219856262, 0.04106304794549942, 0.024273017421364784, 0.1603066623210907, 0.013176793232560158, -0.08835743367671967, -0.057939957827329636, 0.08211691677570343, 0.02175765298306942, -0.08855302631855011, -0.1180030032992363, 0.07023885846138, 0.033809490501880646, 0.0408354327082634, -0.0403791218996048, -0.12580730020999908, -0.004088857211172581, -0.0038295029662549496, 0.09397861361503601, 0.11452168226242065, -0.009621593169867992, -0.10504952073097229, 0.01204186212271452, 0.04042450711131096, 0.12540927529335022, -0.01135712768882513, 0.025410205125808716, 0.10366262495517731, -0.019270366057753563, 0.04868466407060623, 0.20727378129959106, 0.1103188693523407, 0.08673235028982162, -0.06883320212364197, -0.0344981849193573, 0.01334905531257391, 0.06151682510972023, -0.05433005094528198, -0.018208079040050507, -0.03638054430484772, -0.048377975821495056, -0.027304112911224365, 0.09626203775405884, 0.0920136570930481, 0.24390876293182373, 0.05401403829455376, -0.06165962666273117, 0.016511011868715286, 0.08398457616567612, -0.054141685366630554, -0.05524178594350815, 0.0562395416200161, -0.0666792094707489, 0.0459710955619812, -0.0013827253133058548, 0.004357609897851944, -0.21434545516967773, -0.04446636512875557, -0.059110552072525024, -0.0716063529253006, 0.07738658785820007, -0.16528336703777313, -0.08705410361289978, 0.10332872718572617, -0.028619486838579178, -0.14579236507415771, 0.07163682579994202, 0.012232188135385513, -0.012396072968840599, 0.11391440778970718, -0.0008139358833432198, 0.009406957775354385, 0.1159387081861496, -0.1604902446269989, -0.017801327630877495, 0.03186160698533058, 0.16048774123191833, 0.038221538066864014, 0.08504526317119598, 0.09959118068218231, -0.010658590123057365, 1.4980705718390626e-32, 0.015275143086910248, -0.07498069852590561, 0.09084819257259369, 0.046562161296606064, 0.026921989396214485, 0.09673769772052765, 0.06585610657930374, -0.05476091057062149, -0.15738043189048767, -0.09928366541862488, -0.05878067761659622, -0.0513145849108696, 0.038055386394262314, 0.07033133506774902, 0.07285571098327637, -0.11394394934177399, 0.0872214138507843, 0.05665035918354988, -0.021519500762224197, -0.006858988665044308, 0.04276397451758385, 0.057432323694229126, -0.038924701511859894, 0.01262668240815401, -0.15298083424568176, 0.11309480667114258, -0.008214034140110016, 0.16337737441062927, -0.05731211602687836, 0.030653810128569603, -0.19153377413749695, -0.07446302473545074, 0.029436945915222168, -0.01966286450624466, -0.16220387816429138, -0.14327389001846313, -0.03928108513355255, -0.08887974917888641, 0.11119911074638367, 0.027869075536727905, -0.07953262329101562, -0.030493011698126793, 0.025526033714413643, -0.047893788665533066, 0.058421503752470016, -0.15943332016468048, -0.1131325215101242, 0.030136024579405785, -0.07739371061325073, -0.013935192488133907, -0.0009687752462923527, -0.11237629503011703, -0.04178301990032196, 0.004012620076537132, -0.10893090069293976, 0.05104056000709534, -0.23367270827293396, 0.03309880942106247, 0.1301453560590744, 0.014736585319042206, 0.046322718262672424, 0.029592229053378105, 0.17742577195167542, 0.05856093019247055, -0.0014841780066490173, 0.10273924469947815, -0.034555669873952866, -0.17506143450737, -0.1044292226433754, 0.093838170170784, 0.010786768049001694, -0.061931461095809937, 0.18670687079429626, 0.04108903557062149, 0.050645530223846436, 0.0659761056303978, 0.09914428740739822, 0.21809741854667664, -0.029311969876289368, 0.05650762468576431, -0.1753878891468048, -0.0405815914273262, -0.10047465562820435, 0.23029014468193054, -0.000609472393989563, -0.0948403924703598, 0.009755190461874008, -0.04142511636018753, -0.054972995072603226, 0.06654227524995804, 0.13384538888931274, -0.03648757562041283, -0.045923635363578796, 0.06846354156732559, 0.11721716821193695, -1.4413194678228888e-32, 0.019381863996386528, 0.05148770287632942, 0.05746694654226303, -0.1283952295780182, -0.10286818444728851, 0.11971212178468704, 0.10313861072063446, -0.17127859592437744, 0.08422531932592392, -0.14902827143669128, 0.022034432739019394, -0.032393570989370346, -0.07482452690601349, -0.1712161749601364, -0.10281631350517273, 0.012718889862298965, -0.04598290100693703, 0.006988366600126028, -0.08012892305850983, -0.0036721527576446533, 0.050737712532281876, 0.11754890531301498, -0.016787659376859665, -0.017740944400429726, -0.09074702858924866, -0.011642493307590485, 0.1705632209777832, 0.06415107846260071, -0.025170503184199333, -0.011139866895973682, -0.057781752198934555, 0.17222312092781067, -0.2019471675157547, 0.017855975776910782, -0.021627923473715782, -0.05772663652896881, 0.0276287030428648, -0.10790392756462097, -0.07116290181875229, -0.08319465070962906, -0.00891987793147564, 0.20179590582847595, -0.11627689749002457, -0.10887831449508667, -0.001280919648706913, 0.036161065101623535, 0.11929973214864731, 0.07885485887527466, 0.12668068706989288, -0.12449613213539124, -0.07096728682518005, 0.003565929364413023, 0.037816692143678665, 0.02889472432434559, 0.017605531960725784, -0.08353291451931, 0.07630711793899536, -0.0016058939509093761, 0.00045252032577991486, 0.04966796934604645, -0.07006202638149261, -0.0054030874744057655, 0.013296876102685928, -0.025150813162326813, 0.07930420339107513, 0.19436387717723846, 0.044346004724502563, -0.06456004828214645, 0.08745098114013672, -0.00834717508405447, 0.0034917579032480717, -0.017812296748161316, 0.029930036514997482, 0.10494023561477661, 0.0177001915872097, 0.18791720271110535, 0.10669481754302979, -0.12819385528564453, -0.06313734501600266, -0.017691008746623993, -0.18673430383205414, -0.04448285698890686, -0.04865888133645058, -0.009361292235553265, -0.11802482604980469, -0.037805501371622086, 0.030490487813949585, 0.034528542309999466, 0.035155102610588074, 0.046715132892131805, -0.05171690136194229, -0.06640267372131348, -0.011143840849399567, 0.11102087050676346, -0.0438828319311142, -1.0032128727743839e-07, 0.06953226029872894, -0.0979541540145874, -0.0009872457012534142, -0.17268872261047363, -0.017999792471528053, 0.03521592170000076, -0.07637646049261093, -0.035344064235687256, -0.08744187653064728, 0.013377208262681961, -0.006302712019532919, 0.17541667819023132, -0.002076033502817154, -0.09802721440792084, -0.026957323774695396, -0.026626160368323326, 0.16662512719631195, 0.023858703672885895, -0.08313991129398346, -0.029858719557523727, -0.026173798367381096, -0.105447918176651, -0.10132510960102081, -0.09197387844324112, 0.06985732167959213, 0.02715233713388443, 0.004802211187779903, 0.12785333395004272, 0.04573361575603485, -0.06182314455509186, 0.1009242832660675, -0.12106400728225708, 0.08701937645673752, 0.015800386667251587, 0.057752035558223724, 0.0441250279545784, -0.08860287815332413, 0.013600248843431473, 0.01811012253165245, 0.17773546278476715, -0.03603004664182663, -0.1580532193183899, 0.08890443295240402, -0.006737792864441872, -0.11751949787139893, 0.015631673857569695, -0.06554464995861053, -0.08250106871128082, 0.057050853967666626, -0.023798275738954544, 0.045276373624801636, 0.04401799291372299, -0.009869441390037537, -0.10404983907938004, -0.06291654706001282, 0.03726756572723389, -0.05443244427442551, -0.1199282556772232, 0.1343071162700653, -0.07492128759622574, 0.10839628428220749, -0.17353695631027222, 0.03154276683926582, 0.0036094337701797485], "changes": {"1wk": -15.26175862614039, "1mo": -12.067440595485388}}, {"text": "LIVE The latest news and updates on Trump's tariffs Arvinas to Present at Piper Sandler 36th Annual Healthcare Conference Arvinas Inc. Wed, Nov 27, 2024, 3:00 PM 1 min read In This Article: ARVN Arvinas Inc. NEW HAVEN, Conn., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Noah Berkowitz, M.D., Ph.D., Chief Medical Officer and Andrew Saik, Chief Financial Officer will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3 at 2:30 p.m. ET in New York. A live audio webcast of the presentation will be available here and on the Events and Presentations section of the Company\u2019s website. About Arvinas Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC (PROteolysis TArgeting Chimera) protein degrader platform, the Company is pioneering the development of protein degradation therapies designed to harness the body\u2019s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; and ARV-102, targeting LRRK2 for neurodegenerative disorders. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit www.arvinas.com and connect on LinkedIn and X . Contacts Investors: Jeff Boyle +1 (347) 247-5089 Jeff.Boyle@arvinas.com Media: Kirsten Owens +1 (203) 584-0307 Kirsten.Owens@arvinas.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "ARVN", "date": "2024-11-27T15:00:00", "sentiment": {"score": 0.1047028936445713, "confidence": 0.11455445736646652, "probabilities": {"positive": 0.11455445736646652, "negative": 0.009851563721895218, "neutral": 0.8755939602851868}}, "embedding": [-0.13809503614902496, -0.2503508925437927, -0.0877184346318245, -0.12935122847557068, 0.10053933411836624, -0.05694608390331268, -0.014318590983748436, 0.11614778637886047, 0.03250795230269432, 0.1307547390460968, -0.04702924191951752, 0.14038845896720886, -0.06515435129404068, 0.10081014037132263, -0.16595861315727234, 0.12038557976484299, -0.06777343899011612, -0.07892412692308426, 0.024028649553656578, 0.09094016253948212, -0.011480394750833511, 0.03441406041383743, -0.03926205635070801, 0.0614333339035511, -0.04455406218767166, 0.0617712065577507, -0.07764871418476105, -0.018990686163306236, -0.19330252707004547, -0.16611362993717194, 0.09911943227052689, -0.00500753428786993, -0.026778701692819595, -0.0401369072496891, -0.060284677892923355, 0.12574295699596405, -0.10807142406702042, 0.006833839230239391, -0.07159453630447388, -0.06704457104206085, -0.003833406139165163, -0.07133524864912033, -0.14464491605758667, 0.0054244124330580235, 0.008243177086114883, -0.02501770481467247, -0.023564722388982773, 0.027660423889756203, 0.09169977903366089, 0.11317642778158188, -0.04837065935134888, -0.08991958945989609, -0.012086156755685806, 0.08542560786008835, -0.0494912713766098, 0.06207792088389397, -0.13648976385593414, -0.07036010921001434, -0.03133083134889603, -0.037190329283475876, 0.07068140059709549, 0.017206571996212006, -0.015112068504095078, 0.008257434703409672, 0.03290639445185661, -0.01915903575718403, 0.07895253598690033, 0.09461988508701324, 0.043521590530872345, -0.017601249739527702, 0.04742272570729256, -0.07083725929260254, -0.031063906848430634, 0.1997947245836258, -0.0036638325545936823, 0.14078740775585175, 0.19278401136398315, -0.02634487859904766, 0.1686549186706543, -0.13657446205615997, 0.0776151642203331, 0.0038165326695889235, 0.13769812881946564, 0.03377125412225723, 0.01973547972738743, 0.030344974249601364, -0.06600995361804962, 0.011184398084878922, 0.14053960144519806, 0.0011682334588840604, 0.13282839953899384, 0.002882064552977681, 0.033909376710653305, 0.009129741229116917, 0.01695011928677559, -0.026791010051965714, -0.010256171226501465, -0.009308047592639923, -0.024305637925863266, 0.06758391857147217, -0.08045512437820435, 0.03372464329004288, -0.019116932526230812, -0.1977268010377884, -0.009473510086536407, 0.004755268804728985, 0.03905947878956795, 0.06042223796248436, 0.09042427688837051, 0.08124703913927078, -0.052355412393808365, 0.018725894391536713, 0.06971661001443863, -0.022522959858179092, 0.01550688873976469, 0.25780802965164185, -0.034312378615140915, -0.026778195053339005, 0.039332613348960876, -0.09088253974914551, -0.03089367412030697, 0.014834186993539333, 0.04823454096913338, -0.01874230057001114, 0.05833425745368004, 0.17647483944892883, -0.18533563613891602, 1.0238762241857487e-32, 0.02801954746246338, -0.022612011060118675, 0.0315520241856575, 0.06307031959295273, 0.0598725788295269, 0.03378976508975029, 0.010391807183623314, -0.004014594946056604, -0.08381851017475128, -0.1128556951880455, -0.1401260942220688, -0.051165126264095306, 0.021249644458293915, 0.05458953231573105, -0.03818335011601448, -0.05943707376718521, -0.01588684692978859, 0.10097727179527283, -0.059409841895103455, -0.017445838078856468, -0.054804760962724686, 0.060242388397455215, -0.05984039232134819, -0.03745453804731369, 0.08585095405578613, 0.06812253594398499, 0.019885025918483734, 0.08831720054149628, 0.0674784705042839, 0.059441134333610535, -0.1433865875005722, -0.00461131427437067, -0.023706315085291862, -0.04597458988428116, -0.03824800252914429, -0.048624105751514435, -0.0761146992444992, -0.15506692230701447, 0.07127922773361206, 0.036498066037893295, 0.103303924202919, 0.04518092796206474, -0.09157043695449829, 0.060731831938028336, 0.021814581006765366, -0.10127829760313034, 0.01860360987484455, 0.07367974519729614, -0.09244158118963242, -0.060082122683525085, 0.029674973338842392, -0.07477468997240067, 0.0398687869310379, -0.06350544095039368, -0.05260077491402626, -0.0213734470307827, -0.16836315393447876, -0.06746110320091248, 0.20104719698429108, 0.03013555333018303, -0.0034647458232939243, 0.1077723428606987, -0.03305421024560928, 0.043549127876758575, 0.02147332765161991, -0.08882735669612885, -0.008727422915399075, -0.08493068814277649, 0.0065237306989729404, 0.08950092643499374, -0.05618194863200188, -0.07443191856145859, 0.26196837425231934, -0.035620126873254776, 0.05747256428003311, -0.05290323868393898, -0.043742064386606216, 0.10617842525243759, -0.06321019679307938, 0.0530240535736084, -0.10969657450914383, 0.0765472799539566, -0.15027093887329102, 0.17941701412200928, -0.02558874525129795, -0.06704920530319214, 0.07814127951860428, -0.11063364893198013, -0.09445243328809738, -0.025138216093182564, 0.11355962604284286, -0.059785109013319016, -0.002994430484250188, 0.05643297731876373, -0.056893240660429, -7.90674014156343e-33, -0.05767142400145531, -0.039162036031484604, -0.04772631451487541, 0.0019226700533181429, -0.043583307415246964, 0.1185520589351654, 0.18464484810829163, -0.03715243563055992, 0.0921524316072464, -0.22857335209846497, 0.03106611967086792, -0.003941928502172232, -0.017180930823087692, -0.09812501817941666, -0.03018086589872837, 0.020410683006048203, -0.008354377001523972, -0.077062226831913, -0.127732053399086, -0.054648250341415405, 0.05653534084558487, 0.21738910675048828, -0.1104256808757782, 0.021618681028485298, 0.016498522832989693, 0.05407542362809181, 0.12071020901203156, 0.13574914634227753, 0.07800038903951645, -0.03820762038230896, -0.017455458641052246, 0.053734105080366135, -0.1965389996767044, -0.008441487327218056, -0.077062226831913, 0.07609371095895767, 0.0708237960934639, -0.10961396992206573, -0.051744937896728516, -0.2272622436285019, 0.18551425635814667, 0.05040549114346504, -0.1876537799835205, 0.039948079735040665, -0.006366835907101631, 0.10662972182035446, 0.07939466834068298, 0.016430459916591644, 0.12312909215688705, -0.07647816091775894, 0.008605875074863434, -0.1370314657688141, -0.009020290337502956, 0.06768147647380829, 0.022349592298269272, -0.04847860336303711, 0.023378998041152954, -0.0007038273033685982, -0.0697907954454422, 0.08902663737535477, -0.06386537104845047, 0.009177769534289837, 0.08571646362543106, 0.005705257877707481, 0.07426661998033524, 0.16465188562870026, 0.11254805326461792, 0.07097791880369186, -0.006136897951364517, -0.08574999123811722, 0.0047419508919119835, 0.0755113884806633, 0.06262800097465515, 0.05057426169514656, 0.08681567758321762, 0.08914700895547867, -0.040059302002191544, -0.1496783196926117, -0.10440873354673386, -0.1360582411289215, -0.033559251576662064, -0.12993969023227692, -0.09069325029850006, 0.039818160235881805, 0.1348218023777008, 0.03877178579568863, -0.023685121908783913, 0.15759187936782837, -0.01503344252705574, 0.08081578463315964, -0.060616329312324524, -0.14078457653522491, -0.10665678977966309, 0.13807763159275055, 0.06030203029513359, -9.96888189774836e-08, 0.1329682171344757, -0.04538798704743385, 0.021582938730716705, -0.08819045126438141, 0.004289807751774788, 0.013198528438806534, -0.0020522756967693567, 0.09399110078811646, -0.023585006594657898, 0.05502399802207947, 0.06412524729967117, 0.17092818021774292, 0.013869363814592361, 0.0006419750861823559, 0.05169402062892914, 0.09478519856929779, 0.035768184810876846, 0.1237695962190628, -0.16470378637313843, -0.09918133914470673, -0.0529487282037735, 0.05453171953558922, -0.10181829333305359, -0.07124966382980347, 0.07547134906053543, -0.11548750102519989, 0.08471035212278366, 0.0749623253941536, 0.0287480391561985, -0.1721111387014389, -0.05333256721496582, 0.024757882580161095, 0.05296331271529198, 0.030279433354735374, 0.040167227387428284, -0.07832366228103638, 0.013148986734449863, 0.024876141920685768, 0.08492951095104218, 0.1210649162530899, -0.09399548918008804, 0.07410099357366562, -0.08094151318073273, -0.011091177351772785, -0.09632309526205063, -0.07678915560245514, -0.06193583831191063, 0.0034975181333720684, 0.04261195659637451, -0.037345778197050095, -0.004552450962364674, 0.008887617848813534, 0.05589589476585388, -0.13473859429359436, -0.09705168008804321, 0.06988727301359177, -0.12346027046442032, -0.11232107132673264, 0.09551572799682617, -0.033599428832530975, 0.13781175017356873, -0.12896360456943512, 0.10922237485647202, 0.06723938882350922], "changes": {"1wk": -6.889911623241815, "1mo": -26.558890454608257}}]